Name,Term,ES,NES,NOM p-val,FDR q-val,FWER p-val,Tag %,Gene %,Lead_genes
gsea,DNA Repair Pathways Full Network WP4946,0.5578528625624025,2.1022234054457614,0.0,0.027293404094010612,0.02,45/120,20.05%,USP1;PRKDC;FANCI;PCNA;BRCA1;CHEK1;NEIL3;POLE;XRCC5;EXO1;HMGB1;RFC3;POLE2;RFC5;MSH2;FEN1;RFC2;PARP1;RPA3;ERCC5;SMUG1;RPA1;POLD3;RAD23B;RPA2;PARP2;RFC1;FANCL;XRCC4;DDB2;H2AFX;UNG;GTF2H1;PNKP;NHEJ1;MBD4;FANCA;FANCC;RAD51;RFC4;POLD1;RAD50;CETN2;LIG1;POLM
gsea,Regulation of sister chromatid separation at the metaphase-anaphase transition WP4240,0.7921058353204868,2.052781108733931,0.0,0.020470053070507963,0.03,12/15,15.26%,BUB1;BUB1B;RAD21;CENPE;SMC1A;PTTG1;STAG1;MAD2L1;ESPL1;SMC3;BUB3;ANAPC2
gsea,DNA IR-damage and cellular response via ATR WP4016,0.6677861396211301,2.0485923034664792,0.0,0.013646702047005308,0.03,34/80,15.86%,USP1;CDK2;PLK1;PRKDC;FANCI;PCNA;BRCA1;SMC1A;E2F1;CHEK1;CLSPN;CDK1;MCM2;TOPBP1;EEF1E1;XRCC5;EXO1;MDC1;RECQL;FOXM1;RFWD3;MSH2;FEN1;PARP1;RPA1;RPA2;RBBP8;H2AFX;CDC25C;UIMC1;CDC45;FANCA;RAD51;HUS1
gsea,Cell cycle WP179,0.571416032474468,2.01696292218849,0.0,0.013646702047005306,0.04,58/120,26.21%,BUB1;RAD21;CDK2;ORC1;ANAPC1;PLK1;PRKDC;MCM6;TTK;CDC6;CDC25A;PCNA;SMC1A;E2F1;YWHAE;CHEK1;CDK1;MCM2;MCM3;MCM5;YWHAH;PTTG1;STAG1;ORC3;CCND3;CCNB2;CDK6;PKMYT1;ORC6;ESPL1;CDC27;CDC25C;SMC3;BUB3;YWHAZ;CDC7;CDC45;MCM7;ANAPC2;MCM4;CCNB1;RB1;CDC23;ORC4;HDAC2;ORC2;E2F3;YWHAB;CDC20;ANAPC10;SKP1;GSK3B;CUL1;ATR;YWHAQ;CCNE1;SFN;DBF4
gsea,Retinoblastoma gene in cancer WP2446,0.678974655503648,2.0073179876071996,0.0,0.010917361637604246,0.04,49/87,20.41%,KIF4A;RRM1;CDK2;ORC1;PRKDC;MCM6;TTK;TOP2A;CDC25A;PCNA;SMC1A;DHFR;E2F1;CHEK1;POLE;CDK1;TYMS;MCM3;HMGB1;RFC3;POLE2;ANLN;RFC5;PLK4;DCK;RPA3;SIN3A;CCND3;RPA1;POLD3;CCNB2;CDK6;RPA2;SMC2;CCDC6;SUV39H1;SMC3;CDC7;CDC45;POLA1;MCM7;MCM4;RFC4;CCNB1;RB1;E2F3;PRIM1;FAF1;HLTF
gsea,DNA Mismatch Repair WP531,0.7245625517733936,1.8609322358518234,0.0,0.040940106141015925,0.11,13/23,9.13%,PCNA;POLE;EXO1;RFC3;POLE2;RFC5;MSH2;RFC2;RPA3;RPA1;POLD3;RPA2;RFC1
gsea,DNA Replication WP466,0.7511656906775502,1.8494568048486526,0.0,0.04873822159644753,0.14,33/42,20.18%,CDK2;ORC1;MCM6;CDC6;PCNA;POLE;MCM2;MCM3;MCM5;RFC3;POLE2;RFC5;MCM10;RFC2;GMNN;RPA3;ORC3;RPA1;POLD3;RPA2;ORC6;RFC1;PRIM2;CDC7;CDC45;POLA1;MCM7;MCM4;RFC4;POLD1;ORC4;ORC2;PRIM1
gsea,Nucleotide Excision Repair WP4753,0.5275836984656175,1.835561450698461,0.0,0.04264594389689159,0.14,19/44,19.61%,PCNA;POLE;RFC3;POLE2;RFC5;RFC2;RPA3;ERCC5;RPA1;POLD3;RAD23B;RPA2;RFC1;DDB2;GTF2H1;RFC4;POLD1;CETN2;LIG1
gsea,ATM Signaling Network in Development and Disease  WP3878,0.5239164541465912,1.812915081377336,0.0,0.0530705079605762,0.16,12/45,11.25%,AURKB;BUB1;PRKDC;SMC1A;CHEK1;CDK1;MDC1;RNF20;RNF8;LBR;RBBP8;H2AFX
gsea,Base Excision Repair WP4752,0.6071142553453813,1.76828394445118,0.02127659574468085,0.08051554207733132,0.25,13/31,13.21%,PCNA;NEIL3;POLE;HMGB1;POLE2;FEN1;PARP1;SMUG1;POLD3;PARP2;UNG;PNKP;MBD4
gsea,Fluoropyrimidine Activity WP1601,0.5168089523100758,1.7658654071795807,0.023809523809523808,0.07567716589702944,0.27,10/33,19.10%,RRM1;DHFR;TYMS;DPYD;GGH;FPGS;SMUG1;PPAT;UMPS;TK1
gsea,One-carbon metabolism WP241,0.6382182699898588,1.7565101411972703,0.0,0.0796057619408643,0.31,9/30,14.61%,DHFR;TYMS;ATIC;GART;AHCY;MTHFD2;MAT2B;SHMT1;MTHFD1L
gsea,Gastric Cancer Network 2 WP2363,0.6108507079397324,1.7508190740040328,0.0196078431372549,0.07663148072549135,0.31,14/31,19.56%,DSCC1;ATAD2;TOP2A;FANCI;BRIX1;UBE2C;RFC3;UBE2T;LBR;LMNB2;CEBPZ;RFC4;AHCTF1;CACYBP
gsea,G1 to S cell cycle control WP45,0.581576986789816,1.7399579408978516,0.03773584905660377,0.0770063901223871,0.33,30/64,21.29%,CDK2;ORC1;MCM6;CDC25A;PCNA;E2F1;POLE;CDK1;MCM2;MCM3;MCM5;POLE2;RPA3;ORC3;CCND3;RPA1;CDK6;RPA2;ORC6;PRIM2;CDC45;MCM7;MCM4;CCNB1;RB1;ORC4;ORC2;E2F3;PRIM1;CREB1
gsea,ATM Signaling Pathway WP2516,0.5094581487162418,1.7054506371975946,0.0425531914893617,0.1028051554207733,0.38,15/40,21.29%,CDK2;CDC25A;BRCA1;SMC1A;CHEK1;CDK1;MDC1;CASP2;H2AFX;CDC25C;RAD51;CCNB1;RAD50;BID;CREB1
gsea,Nucleotide metabolism WP404,0.5947773127188256,1.7050997383106057,0.0,0.09637983320697499,0.38,8/19,19.04%,RRM1;DHFR;HPRT1;MTHFD2;POLA1;SRM;POLD1;ADSS
gsea,Constitutive Androstane Receptor Pathway WP2875,0.5204959900750227,1.6875976627632572,0.043478260869565216,0.1027516389421576,0.39,9/32,33.03%,SMC1A;ABCC2;HSP90AA1;NCOA6;UGT1A3;DNAJC7;UGT1A1;SP1;ALAS1
gsea,Trans-sulfuration and one-carbon metabolism WP2525,0.6139125826953256,1.6751476543584225,0.061224489795918366,0.11220621683093251,0.44,9/31,14.61%,PSAT1;DHFR;GCLM;TYMS;AHCY;MTHFD2;MAT2B;SHMT1;MTHFD1L
gsea,Amino Acid metabolism WP3925,0.5559174532768891,1.6716806301768252,0.020833333333333332,0.10989186385220062,0.44,41/91,35.65%,FARSB;GOT2;GCLM;RARS;IARS;SMS;EPRS;PC;FH;WARS;LDHA;GLS;MARS2;HADH;PDHA1;GOT1;ALDH18A1;ARG2;LARS2;SRM;SUCLG1;PKM;BCAT1;GPT2;PDHX;MDH1;DLD;ODC1;IDH1;PYCR1;ACADM;CAD;OGDH;P4HA2;CS;GSR;GLUL;FAH;ASNS;GLUD1;ACLY
gsea,Parkin-Ubiquitin Proteasomal System pathway WP2359,0.5525504207417,1.6711398158980475,0.02,0.1043972706595906,0.44,26/70,25.83%,TUBB;TUBA1B;HSPA9;HSPA8;PSMD14;PSMD6;HSPA14;PSMD5;UBA1;HSPA4;PSMD1;PSMD11;TUBB4B;PSMD7;HSPA5;TUBA4A;STUB1;ENST00000629691.2;UBE2G1;PSMC6;PSMD10;TUBB2A;PSMC3;CUL1;CCNE1;PSMD13
gsea,Nuclear receptors WP170,-0.5716750298148215,-1.66748404994682,0.021739130434782608,0.9098451327433629,0.4,6/38,12.48%,ESRRA;NR1H3;NR0B1;NR1H2;RARG;NR2C2
gsea,DNA damage response WP707,0.4654450681703737,1.6674823788286592,0.06976744186046512,0.10007581501137226,0.45,26/68,25.67%,CDK2;PRKDC;CDC25A;BRCA1;SMC1A;E2F1;CHEK1;CDK1;CCND3;CCNB2;CDK6;RPA2;RFC1;DDB2;H2AFX;CDC25C;RAD51;CCNB1;RB1;RAD50;BID;CREB1;CYCS;ATR;CCNE1;SFN
gsea,Integrated Cancer Pathway WP1971,0.5125834541704682,1.6613833716704087,0.0,0.09986904679853884,0.48,8/44,4.87%,CDK2;PLK1;CDC25A;BRCA1;E2F1;CHEK1;CDK1;MSH2
gsea,mRNA Processing WP411,0.4428132428193032,1.6298104692727542,0.0,0.12400698816626561,0.56,42/126,18.04%,DHX9;CPSF3;SNRPD1;SMC1A;SRRM1;NCBP1;SNRPA1;SF3B3;RNGTT;PRPF4B;U2AF1;PAPOLA;PHF5A;HNRNPD;SFSWAP;HNRNPL;CPSF2;DDX20;SNRPF;DHX16;SRSF1;HNRNPA2B1;SRSF7;SF3B1;SNRPD3;CSTF2;U2AF1L5;CLK3;NUDT21;PRMT1;SNRNP40;HNRNPM;HNRNPU;PPM1G;SRSF4;SPOP;CSTF3;HNRNPC;PTBP1;CSTF1;CLASRP;TXNL4A
gsea,Phosphoinositides metabolism WP4971,0.432071144657099,1.604070774144691,0.0,0.14272175890826386,0.6,9/49,19.58%,PIP4K2A;MTMR12;MTMR6;SACM1L;PIK3CB;PIK3C3;PIP5K1A;PIK3R4;PIK3C2A
gsea,Oxidative phosphorylation WP623,-0.47734987754339414,-1.5961249567026448,0.05128205128205128,0.9840523598820058,0.65,24/60,27.22%,NDUFA2;NDUFB10;NDUFA10;ATP5MF;ATP5MC2;ATP5F1E;ATP5ME;NDUFS7;NDUFB4;NDUFS4;NDUFB7;NDUFA11;NDUFA8;ATP5PB;NDUFB9;NDUFS3;NDUFC2;NDUFB2;NDUFB1;NDUFB8;NDUFS5;NDUFS6;ATP6AP1;NDUFB6
gsea,miRNA regulation of DNA damage response WP1530,0.44668939285307485,1.5786986166186403,0.06818181818181818,0.17631539044730857,0.69,27/71,25.67%,CDK2;PRKDC;CDC25A;BRCA1;SMC1A;E2F1;CHEK1;CDK1;CCND3;CCNB2;CDK6;RPA2;RFC1;DDB2;H2AFX;CDC25C;MCM7;RAD51;CCNB1;RB1;RAD50;BID;CREB1;CYCS;ATR;CCNE1;SFN
gsea,Nonalcoholic fatty liver disease WP4396,-0.39562854443953016,-1.5764447170655937,0.02564102564102564,0.7571288102261554,0.67,55/155,27.36%,UQCR11;NDUFA1;ENST00000629738.3;NDUFA2;NR1H3;NDUFB10;NDUFA13;NDUFA10;COX5B;PIK3CD;BBC3;COX7C;UQCRH;BAX;NDUFS7;UQCR10;COX6C;COX4I1;MAP3K11;IRS2;NDUFB4;NDUFS4;NDUFB7;NDUFA11;SMAD7;UQCRB;PRKAG1;NDUFC2-KCTD14;VMP1;NDUFA8;SDHC;NDUFB9;BAK1;UQCRC1;AKT2;MLX;IL6;NDUFS3;DDIT3;NDUFC2;TRAF2;COX7B2;UQCRQ;NDUFB2;NDUFB1;SDHD;NDUFB8;COX7A2;NDUFB3;NDUFS5;CASP3;IRS1;NDUFS6;NDUFB6;COX6B1
gsea,Proteasome Degradation WP183,0.47068345076282286,1.5616552218068838,0.02040816326530612,0.1963025602146148,0.74,24/62,25.83%,UCHL1;PSMD6;PSMB2;PSMD5;UBA1;PSMD1;PSMA5;PSMD11;PSMA4;RPN2;PSMA3;H2AFX;PSMD7;ENST00000629691.2;RPN1;PSMC6;PSMA1;PSMD10;PSMB3;PSME1;PSMC3;UCHL3;PSMA6;PSMD13
gsea,Pathogenic Escherichia coli infection WP2272,0.46319974527269275,1.552836731245018,0.021739130434782608,0.2047005307050796,0.76,16/55,21.90%,TUBB;TUBA1B;ARPC2;ROCK2;TUBB4B;WASL;TUBA4A;YWHAZ;RHOA;ARPC3;ITGB1;ROCK1;NCL;ARPC1A;TUBB2A;CDH1
gsea,DNA IR-double strand breaks and cellular response via ATM WP3959,0.43789971488054086,1.5472314980488038,0.06521739130434782,0.2085995884327954,0.77,15/55,16.57%,PRKDC;PCNA;BRCA1;SMC1A;E2F1;CHEK1;EXO1;MDC1;PARP1;RNF8;H2AFX;CDC25C;SMC3;RAD51;STK3
gsea,Aryl Hydrocarbon Receptor Netpath WP2586,0.40457712417121106,1.5294679471612964,0.02,0.23481739039502234,0.8,14/46,27.15%,CDK2;E2F1;HSP90AA1;MAP2K1;MAPK1;RB1;RNA5SP498;ARNT;NRAS;VEGFA;NFE2L2;KRAS;RAF1;KLF6
gsea,Mitochondrial CIV Assembly WP4922,-0.5183020210250061,-1.5221486280389187,0.02702702702702703,0.8840339233038347,0.74,11/35,10.24%,CMC1;PET117;COX5B;SURF1;COX7C;PET100;COX14;COA3;COX6C;COX4I1;COX11
gsea,Ciliary landscape WP4352,0.36384559058280025,1.5168909355841618,0.07317073170731707,0.25064442759666417,0.81,53/216,22.58%,MCM6;DYNC1LI1;COPS3;MCM2;COPS4;MCM3;MCM5;CNOT9;EIF5B;RNGTT;AIMP1;MCM10;MSH2;RBM14;IQGAP1;CTBP2;RAB8A;ACSL3;COPS8;AFG3L2;IQGAP3;TBC1D4;NUP133;TIPRL;RAB14;DYNC1I2;DDX5;PSMD7;LRPPRC;IFT74;ENST00000629691.2;DOCK5;NEK7;RALB;MCM7;PSMC6;MCM4;RB1;NUP88;MCM8;IFT122;HDAC2;EIPR1;EXOC2;GLA;ANKS6;IFT57;CNOT10;PAFAH1B1;WNK1;MAPRE2;WDR34;RANBP9
gsea,Metabolic reprogramming in colon cancer WP4290,0.5197152122017817,1.5090714681883066,0.09090909090909091,0.2592873388931008,0.81,20/42,25.71%,GOT2;GAPDH;PSAT1;IDH3A;GART;FH;LDHA;GPI;GLS;PGK1;PDHA1;PPAT;FASN;ENO1;SLC1A5;PYCR2;PKM;PGAM1;SDHB;SLC2A1
gsea,Male infertility WP4673,0.3777719360727003,1.4992796184815225,0.0,0.26952236542835484,0.82,13/146,12.54%,TRIP13;PSAT1;XRCC2;PEMT;XRCC5;PARP1;DDX20;PUM2;RFC1;SHMT1;XRCC4;USP8;CDC42BPA
gsea,Gastric Cancer Network 1 WP2361,0.5891369116548956,1.4992699459188505,0.04081632653061224,0.26135502102143493,0.82,7/29,2.48%,TPX2;CENPF;KIF20B;E2F7;TOP2A;MYBL2;UBE2C
gsea,Endoderm differentiation WP2853,0.3795632582202231,1.478159138705991,0.15,0.28658074298711145,0.85,33/141,25.08%,NAA15;HPRT1;NCAPG2;CTBP2;ELP4;NME1;ASCC3;LEO1;CAND1;FOXA1;EZH2;C1QBP;WDHD1;DDAH1;LRPPRC;CEBPZ;BPTF;PIAS1;STAT1;ELAVL1;LAMC1;CDYL;TCF7;NOTCH1;CTR9;SFRP1;ACACA;NABP2;CEP250;RTF1;NLK;CUL4B;NR3C1
gsea,Prion disease pathway WP3995,0.459797354994238,1.4662721767138103,0.0784313725490196,0.30178706812520306,0.86,6/33,21.29%,RAD21;HSP90B1;SMC3;HSPA5;MAPK1;CREB1
gsea,Glycolysis and Gluconeogenesis WP534,0.6135161026624918,1.4628114165755441,0.09259259259259259,0.3009855951478393,0.87,19/45,26.25%,GOT2;GAPDH;ALDOA;PC;LDHA;GPI;PGK1;PDHA1;GOT1;ENO1;TPI1;LDHB;PKM;MPC1;ENO2;PGAM1;MDH1;SLC2A1;DLD
gsea,Sphingolipid pathway WP1422,0.5141283614209493,1.4613952195792173,0.023255813953488372,0.29543265782841216,0.87,11/30,31.81%,PPP2CA;PPP1CA;CERS2;CERS6;PLPP1;SPTLC1;COL4A3BP;SPTLC2;CERS5;SPHK1;SGMS1
gsea,Regulation of Microtubule Cytoskeleton WP2038,0.40367176480664557,1.4369914541964524,0.04878048780487805,0.3433222936036072,0.92,13/46,27.91%,AURKB;KIF2C;CDK1;MAPRE1;DIAPH1;GNAQ;ROCK1;DPYSL2;MARK2;GSK3B;PHLDB2;CLASP1;PIK3CA
gsea,Association Between Physico-Chemical Features and Toxicity Associated Pathways WP3680,0.3874327866619455,1.4311170824923445,0.04081632653061224,0.34781594448008396,0.92,14/66,16.62%,MAP2K4;FN1;MAP2K1;ROCK2;PFN2;PPP2CA;SOS1;DAAM1;NEFH;ACTR2;ACTR3;PFN1;RHOA;MAPK1
gsea,Electron Transport Chain (OXPHOS system in mitochondria) WP111,-0.40289054479191494,-1.4271243305776478,0.1,1.0,0.92,40/103,24.58%,UQCR11;NDUFA1;NDUFA2;NDUFB10;NDUFA10;ATP5MF;ATP5MC2;COX5B;SURF1;ATP5F1E;COX7C;UQCRH;ATP5ME;NDUFS7;UQCR10;COX6C;COX4I1;NDUFB4;COX11;NDUFS4;NDUFB7;UQCRB;NDUFA8;ATP5PB;SDHC;SLC25A6;NDUFB9;UQCRC1;NDUFS3;COX17;NDUFC2;ENST00000647074.2;UQCRQ;NDUFB2;NDUFB1;SDHD;NDUFB8;COX7A2;NDUFB3;NDUFS5
gsea,Circadian rhythm related genes WP3594,0.3237859998921721,1.3979929755542788,0.07692307692307693,0.4240712661106899,0.94,38/201,25.70%,DHX9;PRKDC;TOP2A;TYMS;SUV39H2;PPP1CC;HNRNPD;PRMT5;AHCY;SIN3A;ROCK2;GFPT1;TIMELESS;CSNK1E;EZH2;PPP1CA;SETX;DDX5;HDAC3;SUV39H1;CRY1;HNRNPU;RPS27A;TOP1;GNAQ;RNA5SP498;ARNT;KLF10;HDAC2;PRKAA1;CREB1;SKP1;GSK3B;MAPK8;CUL1;MYBBP1A;METTL3;PTGDS
gsea,NAD Metabolism in Oncogene-Induced Senescence and Mitochondrial Dysfunction-Associated Senescence WP5046,0.4658848927236271,1.3889922755359558,0.07142857142857142,0.4356959263299987,0.94,9/24,28.91%,GOT2;PARP1;GOT1;ELAVL1;RB1;PRKAA1;MDH1;SLC2A1;NAMPT
gsea,G13 Signaling Pathway WP524,0.38960001394072213,1.3834107314575523,0.09090909090909091,0.4418932091411242,0.94,10/39,17.65%,CIT;PIP4K2A;IQGAP1;ROCK2;PIK3CB;WASL;DIAPH1;PFN1;RHOA;ROCK1
gsea,Thyroid stimulating hormone (TSH) signaling pathway WP2032,0.4146706172807245,1.3668289689620703,0.045454545454545456,0.4785866671368373,0.94,21/66,27.91%,CDK2;E2F1;TTF2;CCND3;MAP2K1;JAK1;RAP1B;STAT1;ADCY3;MAPK1;GNAQ;RB1;GNAS;CREB1;PDPK1;MTOR;RAP1A;CCNE1;RAF1;TTF1;PIK3CA
gsea,miRNAs involvement in the immune response in sepsis WP4329,-0.4628243072961498,-1.3427447866744844,0.09090909090909091,1.0,0.96,10/37,26.70%,RELB;TAB1;TAB2;MAPK14;IL6;LCN2;NFKB2;NFKBIA;IRF1;ICAM1
gsea,Ethanol effects on histone modifications WP3996,0.4042057841804845,1.336960740873092,0.1111111111111111,0.5533117375422152,0.96,5/31,11.66%,DHFR;TYMS;AHCY;ALDH2;HDAC3
gsea,Purine metabolism and related disorders WP4224,0.493988895540679,1.333908978334668,0.16326530612244897,0.5485974222896133,0.96,13/22,37.22%,HPRT1;ATIC;GART;PNP;PPAT;PFAS;ADSS;TPMT;MAT2A;PAICS;ADSL;IMPDH1;DGUOK
gsea,Host-pathogen interaction of human coronaviruses - apoptosis WP4864,-0.4505887101057345,-1.332051265644517,0.12195121951219512,1.0,0.96,10/21,30.03%,BBC3;BAX;MAPK13;MAPK14;MAPK11;BAD;FADD;CASP3;BCL2L11;MCL1
gsea,Urea cycle and associated pathways WP4595,0.4840789522591896,1.3234723450893253,0.1590909090909091,0.5684148070013515,0.97,8/24,29.08%,GOT2;FH;GOT1;LDHB;SLC25A13;MDH1;SLC25A12;PYCR1
gsea,7q11.23 copy number variation syndrome WP4932,0.3135862114031133,1.3220760850933437,0.06666666666666667,0.5603858500153244,0.97,21/104,18.97%,BAZ1B;NUP62;PCNA;GAPDH;SMARCA5;RFC5;VPS37A;ATPAF1;RFC2;SF3B1;UBE2E3;DDX21;H2AFX;HDAC3;ATPAF2;TBL2;RB1;BRD4;BCL7B;HDAC2;EIF4H
gsea,Pathways in clear cell renal cell carcinoma WP4018,0.43693653791334197,1.321477288690987,0.1509433962264151,0.5538286580742987,0.97,26/85,25.71%,ME1;GAPDH;PSAT1;PLOD2;ALDOA;LDHA;GPI;PGM2;PGK1;SHMT1;PGM1;TOX2;FASN;ENO1;TPI1;LDHB;ARNT;VEGFA;PKM;ACACA;HIF1A;PHGDH;ENO2;MTOR;MDH1;SLC2A1
gsea,Wnt signaling in kidney disease WP4150,-0.4716272585245834,-1.3135339083769493,0.17073170731707318,1.0,0.97,12/36,29.93%,WNT5A;DVL2;DVL1;FZD7;DVL3;WNT5B;FZD2;WNT6;WNT7B;CTNNB1;WNT10A;LRP5
gsea,3q29 copy number variation syndrome WP4906,0.3847689319583427,1.3120602491409492,0.17307692307692307,0.5745540065912643,0.98,13/63,24.68%,NCBP1;FGFR1OP;TFRC;FBXO45;RNF8;HFE;TM4SF19;RABL2B;STAT5B;HIF1A;WDR34;PAK2;UBE2N
gsea,PDGF Pathway WP2526,0.3610346339148236,1.304502261164459,0.1875,0.5854435178165277,0.98,11/40,23.39%,MAP2K4;MAP2K1;SOS1;JAK1;WASL;PTPN11;STAT1;RHOA;MAPK1;ARFIP2;MAPK8
gsea,16p11.2 proximal deletion syndrome WP4949,0.3674685099234739,1.303733096677156,0.08333333333333333,0.5755697275119297,0.98,17/74,13.76%,CCT8;PCNA;KIF22;ALDOA;MSN;CCT7;PPP2CA;CCT2;CCT6A;CCT5;CCDC6;HDAC3;CCT3;CCT4;PPP4R2;PAXIP1;BPTF
gsea,Pathways affected in adenoid cystic carcinoma WP3651,0.381247713987524,1.301153873631901,0.17307692307692307,0.5692249373068176,0.98,7/65,8.34%,PRKDC;BRCA1;SMC1A;CHEK1;NSD1;KANSL1;DTX4
gsea,Cytoplasmic Ribosomal Proteins WP477,-0.38485217825889595,-1.2982629552404488,0.2619047619047619,1.0,0.98,37/89,23.34%,RPL37;RPL28;RPS13;RPL37A;RPL10A;RPS18;RPL11;RPL13;RPL39;RPS29;RPL13A;RPS2;RPL29;RPS21;RPL9;RPL27A;RPS12;RPLP2;RPLP1;RPL8;RPL31;RPL34;RPL27;RPL23A;FAU;RPL10;RPL7;RPL14;RPL35;RPL18A;RPL7A;RPL12;RPS14;RPS8;RPS5;RPS20;RPLP0
gsea,IL-5 signaling pathway WP127,0.3662239495784413,1.2831093521398833,0.17307692307692307,0.6086944082852933,0.98,11/40,26.80%,MAP2K1;SOS1;JAK1;PTPN11;STAT1;STAT5B;MAPK1;GSK3B;KRAS;RPS6KB2;RAF1
gsea,Pyrimidine metabolism WP4022,0.36748822748605486,1.2818281693783762,0.1836734693877551,0.6007076067728077,0.98,22/85,21.32%,RRM1;POLE;TYMS;POLE2;DPYD;NME1;DCK;PNPT1;POLD3;TWISTNB;PRIM2;POLR2B;DUT;POLA1;UMPS;POLR2K;POLR3F;POLD1;TK1;CMPK1;PRIM1;DTYMK
gsea,Envelope proteins and their potential roles in EDMD physiopathology WP4535,0.34052683181123644,1.2790387704068065,0.1694915254237288,0.5969811840926321,0.98,11/46,23.29%,TMPO;MAP2K1;KIF5B;LBR;SOS1;ADCY3;RHOA;MAPK1;NRAS;LEMD3;KRAS
gsea,Mitochondrial complex I assembly model OXPHOS system WP4324,-0.3831240471917839,-1.2684258804678539,0.2682926829268293,1.0,0.99,23/56,27.22%,NDUFA1;NDUFA2;NDUFB10;NDUFA13;NDUFA10;NDUFB4;NDUFS4;NDUFB7;NDUFA8;TMEM186;NDUFB9;DMAC2;NDUFS3;NDUFC2;NDUFAF1;NDUFB2;NDUFB1;NDUFB8;NDUFB3;NDUFS5;ECSIT;NDUFS6;NDUFB6
gsea,Ferroptosis WP4313,0.3894852021073672,1.2593973731298664,0.15384615384615385,0.6448066717210008,0.99,8/40,11.23%,GCLM;SLC7A11;TFRC;ACSL3;VDAC3;SLC39A14;SLC3A2;SLC39A8
gsea,Thyroid hormones production and their peripheral downstream signaling effects WP4746,0.32782646351810424,1.2473777519407456,0.0975609756097561,0.6677307370017158,0.99,17/95,27.91%,TTF2;MAP2K1;SOS1;TBC1D4;MAP4K5;ADCY3;MAPK1;NOTCH1;MAPKAPK3;GSK3B;MTOR;SECISBP2L;RAF1;TTF1;DIO2;RPTOR;PIK3CA
gsea,Transcription co-factors SKI and SKIL protein partners WP4533,0.4017024888660652,1.2467294332950414,0.21428571428571427,0.6588063057174975,0.99,5/18,16.57%,PRMT5;SIN3A;ING2;HDAC3;STK3
gsea,Toll-like Receptor Signaling related to MyD88 WP3858,-0.45515829286572473,-1.236622485934253,0.16326530612244897,1.0,0.99,3/31,3.50%,RELB;TICAM1;TOLLIP
gsea,AMP-activated protein kinase (AMPK) signaling WP1403,0.3279017980988849,1.2345309335246502,0.20833333333333334,0.6885802032870305,0.99,17/69,27.91%,ENST00000645126.2;PIK3CB;PIK3C3;STRADB;FASN;ELAVL1;CCNB1;PRKACB;PRKAA1;ACACA;CAB39;MTOR;RPS6KB2;CAMKK2;ADIPOR1;RPTOR;PIK3CA
gsea,Oxysterols derived from cholesterol WP4545,0.5413957422759517,1.2325099118084784,0.20408163265306123,0.6855193328278999,0.99,5/46,15.79%,INSIG1;ACOT9;ACOT7;AMACR;DHCR7
gsea,Leptin signaling pathway WP2034,0.2913631859715809,1.2265293656848184,0.18604651162790697,0.6892703115872681,0.99,19/76,24.04%,EIF4E;KPNA4;MAP2K1;ROCK2;SOS1;JAK1;PTPN11;STAT1;RHOA;STAT5B;MAPK1;ROCK1;PRKAA1;ACACA;CREB1;IL1RN;GSK3B;MAPK8;MTOR
gsea,Apoptosis Modulation and Signaling WP1772,-0.328026583705291,-1.2228924215337393,0.15217391304347827,1.0,0.99,22/90,28.22%,CASP6;TRADD;TOLLIP;MAPK3;BBC3;BMF;CFLAR;BAX;BOK;CDKN2A;BCL2L2;BAK1;BAD;RIPK1;BIK;TNFRSF10B;NFKBIA;FADD;CASP3;AIFM2;BCL2L11;TP53
gsea,BDNF-TrkB Signaling WP3676,0.4109351938254327,1.222569445898962,0.1875,0.6889383452762357,0.99,7/34,24.04%,MAP2K1;SOS1;MAPK1;NRAS;CREB1;KRAS;MTOR
gsea,Folate Metabolism WP176,0.352220354307625,1.212382525145044,0.21818181818181817,0.7104949637171016,0.99,7/69,13.75%,DHFR;GART;AHCY;GPX2;MTHFD2;SHMT1;LDLR
gsea,Mesodermal commitment pathway WP2857,0.32449472076891955,1.2096616010596017,0.17073170731707318,0.709628506444276,0.99,25/147,24.46%,HPRT1;NCAPG2;HMGA2;CTBP2;ELP4;ASCC3;HTT;EXT2;PPP2CA;FOXA1;WDCP;C1QBP;WDHD1;DDAH1;CCDC6;PIAS1;TWSG1;CSRP2;BMP4;ACACA;NFE2L2;NABP2;CEP250;NLK;CUL4B
gsea,The Overlap Between Signal Transduction Pathways that Contribute to a Range of LMNA Laminopathies WP4879,0.3500667125625403,1.1976217686201729,0.25,0.7348224179156704,0.99,18/55,32.43%,TMPO;E2F1;NAP1L1;HMGA2;RB1;TCF7;NOTCH1;LEMD3;GSK3B;ZMPSTE24;SPP1;EMD;AGO2;HES1;CDK4;ACTB;FNTA;CSNK1A1
gsea,Rett syndrome causing genes WP4312,0.35934758384229354,1.1708774996385616,0.18604651162790697,0.810117857881315,0.99,6/48,18.09%,SMC1A;HTT;SYNGAP1;TRRAP;CRK;TBL1XR1
gsea,Hedgehog Signaling Pathway WP4249,-0.3721913105808888,-1.1679897796601355,0.21428571428571427,1.0,0.99,7/44,16.62%,FBXL17;CUL3;PTCH1;CSNK1G2;ARRB2;CSNK1D;ARRB1
gsea,Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways WP706,0.34706558562229267,1.1667452669879348,0.24390243902439024,0.8120806128568681,0.99,22/158,25.08%,GAPDH;YWHAE;HSPD1;HSP90B1;FOXM1;CDCA7L;YWHAH;ALDOA;HADHA;YWHAZ;GATA2;PRKACB;VEGFA;YWHAB;MBD1;HIF1A;CREB1;PRKAR2A;IL1RN;MAP2;YWHAQ;NR3C1
gsea,Hippo-Merlin Signaling Dysregulation WP4541,0.30929587131342445,1.1653447921849858,0.2553191489361702,0.8045533603888864,0.99,22/120,31.76%,DCAF1;FOXM1;PPP1CC;PPP1CA;STK3;ITGB1;ITGA6;NRAS;ITGA3;PRKACB;ITGB4;PPP1R12A;PRKAR2A;CDH1;KRAS;TEAD4;PAK2;ITGA5;DDB1;SAV1;PTK2;EPHA2
gsea,Glycerolipids and Glycerophospholipids WP4722,-0.3795473023634366,-1.15966749901962,0.22448979591836735,1.0,0.99,6/22,13.85%,CDIPT;PTDSS2;DGKZ;PNPLA2;PCYT2;GPAT4
gsea,mBDNF and proBDNF regulation of GABA neurotransmission WP4829,0.38816730989534687,1.1582736307713515,0.26666666666666666,0.8162310050433464,0.99,6/38,27.91%,PIK3CB;RHOA;ROCK1;CREB1;AP2B1;PIK3CA
gsea,Type I collagen synthesis in the context of Osteogenesis imperfecta WP4786,0.4514156782584223,1.156391628176264,0.2826086956521739,0.8108090544785012,0.99,9/33,31.14%,PLOD2;TMEM38B;P4HB;P4HA1;COLGALT1;P3H1;MBTPS2;P4HA2;CRTAP
gsea,Neovascularisation processes WP4331,-0.3522097911469655,-1.1536759138653534,0.25,1.0,0.99,3/37,3.63%,EPHB4;RELB;MAPK3
gsea,Translation inhibitors in chronically activated PDGFRA cells WP4566,0.30181493288387357,1.1531137450990447,0.21568627450980393,0.8091917692660893,0.99,13/46,27.91%,MAP2K4;EIF4E;MAP2K1;PIK3CB;RPS6KA4;MAPK1;MAPK8;MTOR;EIF4G3;RPS6KB2;EIF4G1;RPTOR;PIK3CA
gsea,PDGFR-beta pathway WP3972,0.35152237037236567,1.1435207555053726,0.21739130434782608,0.8341546626231995,0.99,10/29,27.91%,MAP2K4;MAP2K1;SOS1;JAK1;STAT1;STAT5B;EIF2AK2;MAPK8;RAF1;PIK3CA
gsea,16p11.2 distal deletion syndrome WP4950,-0.43696822471122615,-1.1430725126617418,0.36363636363636365,1.0,0.99,8/31,28.56%,SH2B1;SPNS1;ATXN2L;IFITM1;TRAF2;GRB2;C3;NFATC2IP
gsea,Genes controlling nephrogenesis WP4823,0.41543582009077895,1.136833504570717,0.2857142857142857,0.8449738801707395,0.99,5/43,19.01%,FOXD1;ITGB1;CD2AP;ITGA3;VEGFA
gsea,"4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression WP3879",0.4068428405483725,1.1363136318632492,0.27450980392156865,0.8342929737925947,0.99,8/18,26.80%,EIF4E;MAP2K1;MKNK2;PBK;MAPK1;PRKAA1;MTOR;RAF1
gsea,Sterol regulatory element-binding proteins (SREBP) signaling WP1982,0.3911315682310706,1.1325387605049058,0.38,0.8333586050037908,0.99,24/69,28.50%,LPIN1;INSIG1;IDI1;CDK8;HMGCS1;CYP51A1;LDLR;SQLE;FASN;SAR1B;SCD;PRKAA1;ACACA;CREB1;SEC23A;MTOR;MVD;FDPS;MDH1;MBTPS2;YY1;PIK3CA;SEC23B;KPNB1
gsea,VEGFA-VEGFR2 Signaling Pathway WP3888,0.26556172757911045,1.1321775120070336,0.30952380952380953,0.8238298551534255,0.99,93/432,24.31%,FARSB;GAPDH;NAP1L1;YWHAE;USP10;FHOD1;MAP2K4;ZC3H15;HMGB1;HSP90AA1;RPS11;DHX29;STIP1;EPRS;FAM120A;FN1;ACOT9;P4HB;PRKCI;ALDOA;MAPKAPK5;IQGAP1;EIF4E;ASCC3;PNP;SSR3;MAP2K1;LDHA;ROCK2;CCT7;PPP2CA;PSMD11;LRRC59;PPP1CA;PGK1;CALU;LMAN1;PDE4DIP;SARS;PBK;PDIA6;RAP1B;PTPN11;GATA2;TMOD3;STAT1;PPM1G;ADAM9;VCL;CRK;PFN1;CTNND1;ELOA;TFAM;ELOC;NRARP;BIRC5;RHOA;MAPK1;ITGB1;ROCK1;ARNT;BRD4;CSRP2;ENG;PRKAA1;VEGFA;UBAP2L;F3;STAM;NCL;FAF1;MAPK12;SPIRE1;ACACA;ACKR3;RAB11A;SRPK1;CREB1;PDPK1;SLC7A1;TXNDC5;QKI;CYCS;TXN;GSK3B;MAPK8;HTRA1;TEAD4;SDF2L1;MTOR;DNAJA1;PAK2
gsea,MAPK Cascade WP422,0.31727275096117047,1.1318459958942737,0.3137254901960784,0.8136624558156023,0.99,9/33,23.29%,MAP2K4;MAP2K1;SOS1;MAP3K2;MAPK1;NRAS;MAPK12;MAP2;KRAS
gsea,Regulation of Actin Cytoskeleton WP51,0.28611982157436044,1.1293538214160108,0.20833333333333334,0.8093544060185456,0.99,34/150,27.91%,PIP4K2A;NCKAP1;FN1;IQGAP1;DIAPH3;MAP2K1;ROCK2;MSN;SOS1;PIK3CB;ENAH;DIAPH1;BAIAP2;PIK3C3;VCL;CRK;PIP5K1A;PFN1;GNG12;PIK3R4;RHOA;MAPK1;ROCK1;NRAS;PIK3C2A;PPP1R12A;KRAS;PAK2;SSH1;SSH3;MAPK6;RAF1;CSK;PIK3CA
gsea,Extracellular vesicle-mediated signaling in recipient cells WP2870,-0.3595337517370345,-1.1284474645170175,0.26666666666666666,1.0,0.99,4/30,9.13%,EGFR;WNT5A;ERBB2;MFGE8
gsea,Vitamin D-sensitive calcium signaling in depression WP4698,-0.4014054469187079,-1.1170000277289152,0.2830188679245283,1.0,0.99,3/41,8.60%,KDM6B;GPX4;GGT1
gsea,MECP2 and Associated Rett Syndrome WP3584,0.3422772689548167,1.1139567300204942,0.28,0.853350735597547,0.99,11/72,24.08%,DHX9;E2F1;PRPF38A;SIN3A;EZH2;SMC3;TARDBP;CREB1;HNRNPH1;MTOR;FUS
gsea,Photodynamic therapy-induced AP-1 survival signaling. WP3611,-0.3052290152511312,-1.1117730879747316,0.23404255319148937,1.0,1.0,13/50,20.87%,JUNB;BMF;EGFR;CFLAR;BAX;CDKN2A;MAPK13;MAPK14;BAK1;MAPK11;IL6;BCL3;TRAF2
gsea,One-carbon metabolism and related pathways WP3940,0.3472760371667896,1.1106978990705743,0.2978723404255319,0.8559893858984079,0.99,15/52,32.90%,GCLM;PEMT;TYMS;GPX2;SHMT1;CHPT1;CEPT1;DNM1;BCAT1;AHCYL1;MAT2A;SOD1;SOD2;GSR;ETNK1
gsea,Sphingolipid Metabolism (integrated pathway) WP4726,0.42663906405304763,1.110436588203191,0.3541666666666667,0.8471063937326258,0.99,8/25,31.81%,CERS2;CERS6;SPTLC1;SMPD1;SPTLC2;CERS5;SPHK1;SGMS1
gsea,Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling WP3612,0.346987064316468,1.1104234270839541,0.3333333333333333,0.8367758279553985,0.99,8/24,25.88%,GCLM;ABCC2;NQO2;MAPK12;NFE2L2;MAPK8;SRXN1;HMOX1
gsea,Hereditary leiomyomatosis and renal cell carcinoma pathway WP4206,0.3337987555803002,1.1092332732581627,0.32,0.8303113896069495,0.99,8/20,25.71%,LDHA;PDHA1;PRKAA1;VEGFA;ACACA;HIF1A;NFE2L2;SLC2A1
gsea,Signaling of Hepatocyte Growth Factor Receptor WP313,0.3020646777035711,1.1063595572171987,0.2553191489361702,0.8288746886169176,0.99,12/34,27.91%,MAP2K1;SOS1;RAP1B;PTPN11;CRK;MAPK1;ITGB1;MAPK8;CRKL;RAP1A;RAF1;PIK3CA
gsea,Melatonin metabolism and effects WP3298,0.3926308391967595,1.1054739966959641,0.3469387755102041,0.8215314632297194,0.99,10/37,41.35%,CSNK1E;CRY1;MAP2;GSK3B;IRAK1;CALM1;CALM2;ECE1;CYP1B1;PRKCA
gsea,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932,0.27312829896331486,1.100306058294589,0.30952380952380953,0.8283230777368338,0.99,63/303,33.27%,HSP90B1;HSP90AA1;FN1;EIF4E;RAB8A;MAP2K1;PPP2CA;SOS1;FOXA1;JAK1;PPP2R1B;PIK3CB;RAB14;OSMR;KITLG;PPP2R5A;GNG12;ELAVL1;PIK3R4;LAMC1;HSP90AB1;MAPK1;ITGB1;ITGA6;NRAS;ITGA3;IL4R;GNB4;PRKAA1;VEGFA;PIK3C2A;ITGB4;EPAS1;ACACA;HIF1A;CREB1;PDPK1;IFNAR1;GSK3B;CAB39;KRAS;MTOR;LAMA5;RPS6KB2;LAMA3;SPP1;SLC2A1;RAF1;RPTOR;PIK3CA;LPAR5;ITGA5;PPP2R3A;PPP2R2C;PFKFB3;PELO;PTK2;PPP2CB;EPHA2;VEGFC;LAMC2;GNG10;RPS6KB1
gsea,PI3K-Akt signaling pathway WP4172,0.2653274241334025,1.0998063291546583,0.36,0.8199001333298476,0.99,59/340,33.27%,CDK2;BRCA1;HSP90B1;HSP90AA1;FN1;EIF4E;CCND3;MAP2K1;CDK6;PPP2CA;SOS1;JAK1;PPP2R1B;PIK3CB;OSMR;KITLG;PPP2R5A;GNG12;LAMC1;HSP90AB1;MAPK1;THEM4;ITGB1;ITGA6;NRAS;ITGA3;IL4R;GNB4;PRKAA1;VEGFA;ITGB4;CREB1;PDPK1;IFNAR1;GSK3B;KRAS;MTOR;LAMA5;PKN2;RPS6KB2;LAMA3;SPP1;CCNE1;RAF1;RPTOR;PIK3CA;LPAR5;ITGA5;PPP2R3A;CHUK;PPP2R2C;CDK4;PTK2;PPP2CB;EPHA2;VEGFC;LAMC2;GNG10;RPS6KB1
gsea,Notch Signaling WP268,-0.2792694271516646,-1.0980969446751867,0.2708333333333333,1.0,1.0,11/45,23.09%,APH1A;MFNG;DTX2;DVL2;NUMB;INPP5K;NUMBL;DVL1;DVL3;RFNG;DTX3
gsea,Photodynamic therapy-induced NF-kB survival signaling WP3617,-0.4268224098894752,-1.0878512028036829,0.375,1.0,1.0,7/35,21.53%,EGLN2;RELB;CFLAR;BCL2L2;PTGS2;IL6;NFKB2
gsea,Cholesterol metabolism (includes both Bloch and Kandutsch-Russell pathways) WP4718,0.45668658980856575,1.086351752692137,0.41509433962264153,0.8555551726514578,0.99,19/46,25.20%,HSD17B7;ELOVL5;ACSL3;LBR;IDI1;HMGCS1;CYP51A1;SOAT1;SQLE;FASN;MSMO1;DHCR7;GGPS1;SCD;SC5D;DHCR24;MVD;FDPS;FADS1
gsea,Glycogen Synthesis and Degradation WP500,0.36564059819176264,1.0847370501684652,0.391304347826087,0.8503888713785555,0.99,17/40,37.40%,HKDC1;PPP2CA;PPP2R1B;PGM1;PPP2R5A;AGL;GSK3B;PPP2R3A;PPP2R2C;PPP2CB;PHKA2;HK2;GYG1;GYS1;CALM1;CALM2;UGP2
gsea,Glycerophospholipid Biosynthetic Pathway WP2533,0.36762179325149896,1.082821429135434,0.3488372093023256,0.8473085670962851,0.99,8/30,18.05%,LPIN1;PEMT;GNPAT;PTDSS1;PIK3CB;PIP5K1A;CHPT1;CEPT1
gsea,Androgen receptor signaling pathway WP138,0.24968823905803103,1.0813963029242672,0.28888888888888886,0.8426463604628881,0.99,16/90,17.65%,BRCA1;RNF4;KAT7;SIN3A;ROCK2;RAN;PRDX1;PARK7;PLPP1;STUB1;PIAS1;RNF6;RHOA;RB1;RNF14;ROCK1
gsea,Oncostatin M Signaling Pathway WP2374,0.2706706975024734,1.0802625238683357,0.42,0.8371955038401951,0.99,16/65,24.04%,CDK2;MAP2K1;SOS1;JAK1;OSMR;PTPN11;LDLR;STAT1;STAT5B;MAPK1;VEGFA;HIF1A;CREB1;KRAS;MAPK8;MTOR
gsea,Photodynamic therapy-induced unfolded protein response WP3613,0.3504980686886093,1.0801931704900554,0.2826086956521739,0.8284868791117415,0.99,14/27,34.18%,HSP90B1;WARS;DNAJC3;PDIA6;HSPA5;NARS;EDEM1;XBP1;NFE2L2;DNAJB11;TRIB3;EIF2A;DNAJB9;ASNS
gsea,Integrated breast cancer pathway WP1984,0.25584449978164003,1.0778654622871748,0.3673469387755102,0.8288193828335457,0.99,30/152,25.16%,CDK2;PLK1;CDC25A;BRCA1;E2F1;CHEK1;RAD54L;MSH2;DHTKD1;JAK1;TPR;USP16;NUP85;PIAS1;STAT1;ERAL1;RAD51;MAPK1;RB1;RNA5SP498;VEGFA;RAD50;BID;CREB1;CDH1;AURKA;KRAS;MTOR;ATR;RAP1A
gsea,Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells WP4301,0.34034438279510004,1.0758141802634704,0.38,0.8267028450580584,1.0,10/18,29.77%,PDCD6IP;MAPK1;NRAS;HNRNPH1;KRAS;RAB5C;RAF1;RAB27A;RAB5B;RAB5A
gsea,Nephrotic syndrome WP4758,0.32086340750188874,1.0697314025537759,0.40384615384615385,0.8344389689158453,1.0,12/45,24.61%,ANLN;COQ2;PDSS2;PODXL;CD2AP;ITGA3;E2F3;ITGB4;SMARCAL1;INF2;EMP2;ZMPSTE24
gsea,Differentiation Pathway WP2848,-0.3742006626739463,-1.0668552273634098,0.41304347826086957,1.0,1.0,7/48,20.51%,DKK1;WNT5A;NTF4;PDGFB;CSF1;IL6;NT5E
gsea,Histone Modifications WP2369,0.32119202507918204,1.061971412353913,0.4782608695652174,0.848346529313835,1.0,7/67,11.98%,SUV39H2;NSD1;SETD5;EZH2;ASH1L;SMYD5;SUV39H1
gsea,PPAR-alpha pathway WP2878,-0.37076215425482173,-1.0556546486904668,0.32558139534883723,1.0,1.0,5/26,17.31%,NR1H3;SLC27A1;PLTP;MYC;CPT1A
gsea,Photodynamic therapy-induced HIF-1 survival signaling WP3614,0.3398126895286837,1.0534118059781816,0.4090909090909091,0.8633627825656418,1.0,10/37,21.04%,LDHA;PGK1;PDHA1;BIRC5;ENST00000630362.2;ARNT;VEGFA;PKM;HIF1A;BID
gsea,"GPCRs, Class A Rhodopsin-like WP455",0.3703580983552551,1.0505349265043555,0.36363636363636365,0.8633262113171136,1.0,6/257,20.76%,GRPR;P2RY6;ADORA2B;F2RL1;PTAFR;ACKR3
gsea,Glycosylation and related congenital defects WP4521,0.34750597247893605,1.0442831969452862,0.3958333333333333,0.8703866565579985,1.0,10/25,36.36%,DPM2;ALG3;ALG11;DPAGT1;MOGS;ALG13;ALG8;B4GALT1;ALG2;MPDU1
gsea,Estrogen signaling pathway WP712,0.4011669798818195,1.0438268900109926,0.3617021276595745,0.8627147779220682,1.0,7/23,31.62%,MAP2K1;MAPK1;GNAS;CREB1;PIK3CA;CHUK;SP1
gsea,Effect of progerin on genes involved in Hutchinson-Gilford progeria syndrome WP4320,0.31656158479596463,1.042039775253974,0.36538461538461536,0.8584043169959418,1.0,6/37,18.86%,E2F1;CBX5;SUV39H1;MBD2;RB1;HDAC2
gsea,Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms WP4534,0.29320307408266977,1.0399111597365835,0.36,0.8548400156046431,1.0,12/47,32.15%,MAP4K5;STK3;ITGB1;ITGB4;CDH1;MAPK8;TEAD4;PAK2;YWHAQ;SAV1;SGMS1;ACTB
gsea,Endometrial cancer WP4155,-0.279081271634314,-1.036943857394449,0.35555555555555557,1.0,1.0,12/63,17.05%,GADD45A;PIK3CD;MAPK3;EGFR;ERBB2;BAX;GADD45B;MAP2K2;BAK1;AKT2;BAD;MYC
gsea,Amyotrophic lateral sclerosis (ALS) WP2447,-0.33545004345874907,-1.0328193442508524,0.42,1.0,1.0,12/38,29.53%,CCS;CAT;BAX;MAP2K2;MAPK14;BAD;PPP3CA;DERL1;CASP3;CST3;TP53;GPX1
gsea,Oxidative Damage WP3941,-0.3220333892504082,-1.0322977931620954,0.3695652173913043,1.0,1.0,8/40,20.87%,GADD45A;TNK2;C1R;MAPK13;BAK1;BAD;C1S;TRAF2
gsea,Fas ligand pathway and stress induction of heat shock proteins WP314,0.3236539753852757,1.0253070110251055,0.38461538461538464,0.8897912171225288,1.0,13/42,24.31%,PRKDC;MAP2K4;LMNB1;PARP1;LMNB2;RB1;FAF1;RIPK2;SPTAN1;MAPKAPK3;CYCS;MAPK8;PAK2
gsea,Common Pathways Underlying Drug Addiction WP2636,0.3423536484853538,1.0244768838136096,0.4,0.8840463554640962,1.0,10/42,26.80%,PPP1CC;MAP2K1;PPP1CA;RAP1B;MAPK1;GNAS;PRKACB;CREB1;RAP1A;RAF1
gsea,Cytosolic DNA-sensing pathway WP4655,-0.2993901612951187,-1.0243526686296904,0.43859649122807015,1.0,1.0,17/75,27.93%,TRADD;POLR1D;PYCARD;POLR2F;POLR3A;POLR3GL;TREX1;IL6;POLR1C;RIPK1;MAVS;POLR3C;NFKBIA;FADD;IL18;POLR3H;POLR3B
gsea,miRNA regulation of prostate cancer signaling pathways WP3981,0.33597422309090097,1.0223546190559236,0.4339622641509434,0.8830446164189566,1.0,9/33,27.91%,MAP2K1;SOS1;MAPK1;TCF7;GSK3B;KRAS;MTOR;RAF1;PIK3CA
gsea,"Relationship between inflammation, COX-2 and EGFR WP4483",-0.34351532135596075,-1.020471850470192,0.4634146341463415,1.0,1.0,5/25,17.23%,PIK3CD;MAPK3;EGFR;AKT2;PTGS2
gsea,Genes related to primary cilium development (based on CRISPR) WP4536,0.26578196194008424,1.019140433895089,0.4444444444444444,0.8812963658393148,1.0,13/103,23.36%,FGFR1OP;TEDC2;FOPNL;KATNB1;MKKS;OFD1;IFT74;TMEM107;IFT122;IFT57;TCTN3;WDR34;TCTN1
gsea,Prader-Willi and Angelman Syndrome WP3998,0.33049163725612074,1.0157465452742922,0.42,0.8822340156684357,1.0,7/61,24.76%,CDC6;E2F1;CDK6;NIPA2;RB1;CYFIP1;FEZ2
gsea,Neural Crest Cell Migration during Development WP4564,-0.30203758593020386,-1.0133819901598031,0.44680851063829785,1.0,1.0,3/40,7.27%,EPHB4;PIK3CD;TRIO
gsea,TCA Cycle (aka Krebs or citric acid cycle) WP78,0.35040344769645426,1.0121329122408684,0.43137254901960786,0.8837804564202794,1.0,7/18,30.45%,IDH3A;FH;SUCLG1;SDHB;DLD;OGDH;CS
gsea,TLR4 Signaling and Tolerance WP3851,-0.34807054304224283,-1.0101161810048969,0.45098039215686275,1.0,1.0,6/28,23.74%,TICAM1;TAB1;TAB2;IL6;RIPK1;NFKBIA
gsea,CAMKK2  Pathway WP4874,0.3191077398530976,1.0071908535798895,0.4,0.8896409125370459,1.0,11/34,27.70%,SMC1A;DNM1L;MAPK1;CREB1;NFE2L2;MTOR;HMOX1;CAMKK2;RAF1;WFS1;RPTOR
gsea,Tryptophan metabolism WP465,0.41941332842283474,1.0042732229033342,0.42857142857142855,0.8892486117656703,1.0,9/42,29.61%,WARS;HADH;ALDH2;PRMT1;ALDH9A1;DHCR24;ACAT1;HSD17B10;OGDH
gsea,Sphingolipid Metabolism (general overview) WP4725,0.40850528585166257,1.0003226101651548,0.4489795918367347,0.891178381891043,1.0,7/24,31.81%,CERS2;CERS6;SPTLC1;SMPD1;SPTLC2;SPHK1;SGMS1
gsea,Neural Crest Cell Migration in Cancer WP4565,-0.29169144829055144,-0.9998438281126015,0.46938775510204084,1.0,1.0,3/43,7.27%,EPHB4;PIK3CD;TRIO
gsea,Synaptic Vesicle Pathway WP2267,0.33640002530280305,0.9989627947576455,0.4375,0.8867940985058405,1.0,9/51,38.27%,DNM1L;PARK7;DNM2;DNM1;AP2B1;NSF;AP2M1;SLC25A4;AP2A1
gsea,Hepatitis C and Hepatocellular Carcinoma WP3646,0.30588891160814813,0.9987556858716959,0.5,0.8791349108176051,1.0,10/49,23.39%,BRCA1;UCHL1;SOS1;JAK1;PTPN11;BIRC5;PODXL;VEGFA;HIF1A;MAPK8
gsea,Regulation of toll-like receptor signaling pathway WP1449,-0.2679485199430609,-0.9951328224648459,0.46808510638297873,1.0,1.0,26/139,24.51%,PTPN6;TICAM1;CUEDC2;TOLLIP;PIK3CD;MAPK3;RNF41;TAB1;TRAFD1;USP7;MAP2K2;TAB2;MAPK13;MAPK14;MAPK11;AKT2;SIGIRR;IL6;OTUD5;RIPK1;RBCK1;NFKB2;PELI1;NFKBIA;FADD;TAB3
gsea,Apoptosis-related network due to altered Notch3 in ovarian cancer WP2864,0.27244038457220215,0.9944638086632559,0.4489795918367347,0.8838316247486566,1.0,12/53,24.31%,ANXA5;NET1;HSPD1;HELLS;SERBP1;HSPA5;BIRC5;MAPK1;CUL5;RIPK2;CUL1;PAK2
gsea,Modulators of TCR signaling and T cell activation WP5072,-0.2939638072429711,-0.9916579958615628,0.4782608695652174,1.0,1.0,6/61,11.15%,NDUFB10;PTPN6;DGKZ;ARIH2;RNF7;ZFP36L1
gsea,G Protein Signaling Pathways WP35,0.26785923172838944,0.9915707970898475,0.5098039215686274,0.884682753392068,1.0,13/93,23.29%,PRKCI;PDE8A;ADCY3;GNG12;RHOA;AKAP11;GNAQ;GNAS;NRAS;PRKACB;AKAP10;PRKAR2A;KRAS
gsea,Angiopoietin Like Protein 8 Regulatory Pathway WP3915,0.22236023513413708,0.982508534780538,0.4878048780487805,0.8989327579168368,1.0,29/132,27.91%,MAP2K4;EIF4E;MAP2K1;SOS1;MAP4K5;PIK3CB;RPS6KA4;PIK3C3;FASN;CRK;PIK3R4;MAP3K2;MAPK1;SCD;PRKAA1;PIK3C2A;MAPK12;PDPK1;RPS6KA3;GSK3B;MAPK8;MTOR;MAPK6;RPS6KB2;SLC2A1;RAF1;DIO2;RPTOR;PIK3CA
gsea,Host-pathogen interaction of human coronaviruses - autophagy WP4863,0.3269510615712632,0.9766466410415063,0.5121951219512195,0.9073900361085054,1.0,4/19,15.67%,ATG3;ATG4A;PIK3C3;PIK3R4
gsea,Regucalcin in proximal tubule epithelial kidney cells WP4838,0.3309735598967152,0.9764656919065504,0.5111111111111111,0.9003383005969636,1.0,7/33,27.91%,PPP3R1;MCU;MAPK1;MTOR;G3BP1;RAF1;PIK3CA
gsea,TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway WP2036,-0.3122653164521107,-0.9758171365450994,0.4666666666666667,1.0,1.0,12/42,25.27%,RELB;MAPK3;TNFRSF12A;MAPK14;AKT2;IL6;RIPK1;TRAF2;NFKB2;NFKBIA;FADD;CASP3
gsea,RANKL/RANK signaling pathway WP2018,-0.2590853836794079,-0.9739328015972397,0.4166666666666667,1.0,1.0,13/55,26.70%,RELB;MAPK3;TAB1;FHL2;TAB2;MAPK14;AKT2;TRAF2;NFKB2;GAB2;NFKBIA;PAPSS2;ICAM1
gsea,Endoplasmic reticulum stress response in coronavirus infection WP4861,0.3056899587382292,0.9734321471873969,0.5,0.9026156178923426,1.0,12/47,30.18%,PPP1CC;PPP1R7;PPP1CA;HSPA5;EIF2S1;EIF2AK2;XBP1;PPP1R12A;MAPK8;MBTPS2;PPP1R8;EIF2AK1
gsea,Joubert Syndrome WP4656,0.2698170406712851,0.9694615138469044,0.5,0.9030507709948056,1.0,11/76,24.04%,PARP1;RAB8A;TMEM138;OFD1;RHOA;RAD50;CETN2;ANKS6;TCTN3;TCTN1;MTOR
gsea,Vitamin D Receptor Pathway WP2877,-0.25365503121148697,-0.9681097652339192,0.5384615384615384,1.0,1.0,17/182,20.19%,EPHB4;GADD45A;CDC34;CDKN2B;JUNB;CST6;HILPDA;TPM1;CDKN2A;LGALS9;CLPTM1L;MYC;KRT16;TRAK1;ITGAM;ATP2B1;MYO9B
gsea,Resistin as a regulator of inflammation WP4481,-0.3409654792515816,-0.9654947683874419,0.5106382978723404,1.0,1.0,7/33,23.74%,PIK3CD;MAPK3;MAPK14;AKT2;IL6;PLCD3;NFKBIA
gsea,Complement and Coagulation Cascades WP558,-0.3279958513997946,-0.964173692805084,0.52,1.0,1.0,5/58,17.18%,SERPINF2;C8G;PROC;C1R;C1S
gsea,White fat cell differentiation WP4149,-0.2863867542627419,-0.9593769605296926,0.5185185185185185,1.0,1.0,5/32,20.47%,NR1H3;KLF15;CEBPB;CEBPD;DDIT3
gsea,Corticotropin-releasing hormone signaling pathway WP2355,0.25848867647959545,0.9583821527667672,0.5918367346938775,0.9232776942293591,1.0,14/93,23.39%,HSP90AA1;PRKCI;PARP1;MAP2K1;GRK6;RAP1B;RHOA;MAPK1;GNAQ;GNAS;ACACA;CREB1;GSK3B;MAPK8
gsea,MET in type 1 papillary renal cell carcinoma WP4205,0.2526431459898612,0.9532843303232559,0.5306122448979592,0.9303056639360936,1.0,17/59,27.91%,MAP2K1;SOS1;STRN;PIK3CB;RAP1B;PTPN11;CRK;ELOA;MAPK1;NRAS;KRAS;MAPK8;CRKL;PAK2;RAP1A;RAF1;PIK3CA
gsea,Genotoxicity pathway WP4286,-0.2837617024306374,-0.9525855927080867,0.5,1.0,1.0,6/63,6.03%,SERTAD1;GADD45A;RAPGEF2;PHLDA3;ENST00000643983.1;HIST1H2BC
gsea,TGF-beta Signaling Pathway WP366,0.20821427154751837,0.9425103624958077,0.5625,0.9528479542175158,1.0,25/132,24.31%,MAP2K4;CDK1;NUP153;FN1;SIN3A;MAP2K1;CCNB2;SOS1;STAMBPL1;PIAS1;RHOA;MAPK1;NUP214;TRAP1;ITGB1;ROCK1;KLF10;ITGB4;SNW1;PRKAR2A;PPM1A;SKP1;MAPK8;CUL1;PAK2
gsea,Wnt signaling pathway and pluripotency WP399,0.2753931817859316,0.9419191237037108,0.6428571428571429,0.9474086429112963,1.0,16/102,24.41%,MAP2K4;PRKCI;CTBP2;CCND3;PPP2CA;CSNK1E;RACGAP1;PPP2R1B;LDLR;CTNND1;RHOA;TCF7;PAFAH1B1;GSK3B;PPARD;NLK
gsea,The influence of laminopathies on Wnt signaling WP4844,0.2863228970637372,0.9412094644436128,0.5882352941176471,0.9414058269251597,1.0,14/35,36.11%,HMGA2;CDK6;TCF7;GSK3B;TOR1AIP1;ZMPSTE24;SPP1;EMD;AGO2;HES1;FNTA;CSNK1A1;ICMT;PPARG
gsea,Type 2 papillary renal cell carcinoma WP4241,0.2848602092558843,0.9377107339474636,0.5,0.9437715281799026,1.0,9/34,20.97%,FH;DIAPH1;ELOC;ELOB;CUL2;ARNT;VEGFA;EPAS1;HIF1A
gsea,RAC1/PAK1/p38/MMP2 Pathway WP3303,0.24987274283748867,0.9316837500025805,0.660377358490566,0.9512177786201668,1.0,16/68,23.39%,FN1;MSH2;SOS1;PTPN11;CRK;RAD51;BIRC5;STAT5B;MAPK1;ITGB1;NRAS;TNIP1;MAPK12;TNIP2;KRAS;MAPK8
gsea,Glioblastoma signaling pathways WP2261,0.24051665826661162,0.9243005065856224,0.5961538461538461,0.9616164465680485,1.0,8/82,10.05%,CDK2;BRCA1;E2F1;MAP2K4;PRKCI;MAP2K1;CDK6;PIK3CB
gsea,Exercise-induced Circadian Regulation WP410,0.27983635842334964,0.9170491776068488,0.6428571428571429,0.9716451857467778,1.0,14/48,31.75%,HSPA8;NCKAP1;IDI1;PSMA4;CRY1;ZFR;QKI;DNAJA1;AZIN1;SUMO1;NCOA4;SUMO3;SF3A3;PPP2CB
gsea,Apoptosis WP254,-0.2695552876387291,-0.9169402438404797,0.5434782608695652,1.0,1.0,22/84,28.22%,CASP6;TRADD;BBC3;CFLAR;BAX;BOK;CDKN2A;BCL2L2;BAK1;IRF6;BAD;MYC;TNFRSF21;RIPK1;TRAF2;TNFRSF10B;NFKBIA;FADD;CASP3;IRF1;BCL2L11;TP53
gsea,Endochondral Ossification WP474,0.2927040743364481,0.915985941599828,0.5660377358490566,0.9594045075470397,1.0,7/64,25.50%,HMGCS1;STAT1;STAT5B;CHST11;VEGFA;CAB39;SPP1
gsea,Endochondral Ossification with Skeletal Dysplasias WP4808,0.2927040743364481,0.915985941599828,0.5660377358490566,0.9594045075470397,1.0,7/64,25.50%,HMGCS1;STAT1;STAT5B;CHST11;VEGFA;CAB39;SPP1
gsea,Primary focal segmental glomerulosclerosis (FSGS) WP2572,0.24099416218710437,0.9146105561159845,0.5961538461538461,0.9554743568549882,1.0,15/72,24.85%,MKI67;PCNA;FAT1;VCL;PODXL;ITGB1;CD2AP;ITGA3;NOTCH1;ITGB4;DNM1;SMARCAL1;INF2;YWHAQ;LAMA5
gsea,NRF2 pathway WP2884,0.23360899045543249,0.9133089696984724,0.6521739130434783,0.9521120704287509,1.0,19/146,25.88%,ME1;GCLM;ABCC2;SLC7A11;HSP90AA1;GPX2;SLC39A14;PRDX1;SLC39A8;HSP90AB1;SLC39A9;UGT1A3;NFE2L2;TXN;PPARD;SLC6A6;SRXN1;SLC2A1;HMOX1
gsea,Chemokine signaling pathway WP3929,0.22858873378975583,0.9072063489782886,0.5434782608695652,0.9602223907000254,1.0,24/164,27.91%,MAP2K1;ROCK2;SOS1;GRK6;PIK3CB;WASL;RAP1B;STAT1;ADCY3;CRK;GNG12;STAT5B;MAPK1;ROCK1;NRAS;GNB4;PRKACB;GSK3B;KRAS;CRKL;RAP1A;RAF1;CSK;PIK3CA
gsea,Integrin-mediated Cell Adhesion WP185,0.24187549010745737,0.9066981694702416,0.5869565217391305,0.9545667395085404,1.0,21/101,28.16%,MAP2K1;ROCK2;SOS1;RAP1B;CAPNS1;VCL;CRK;MAPK1;ITGB1;ROCK1;ITGA6;ITGA3;ITGB4;MAPK12;PDPK1;PAK2;RAP1A;MAPK6;RAF1;CSK;ITGA5
gsea,TNF-alpha signaling pathway WP231,0.2145507194582634,0.9065364991725176,0.7021276595744681,0.9478979319657116,1.0,17/92,23.86%,PLK1;MAP2K4;HSP90AA1;NSMAF;PPP2CA;SOS1;RFFL;TBK1;MAPK1;TRAP1;NRAS;BID;SKP1;TXN;KRAS;MAPK8;CUL1
gsea,IL-2 signaling pathway WP49,0.2825906432978773,0.9056980556834726,0.6274509803921569,0.9437980024392657,1.0,10/42,26.80%,MAP2K1;SOS1;JAK1;PTPN11;STAT1;STAT5B;MAPK1;CRKL;RPS6KB2;RAF1
gsea,EPO Receptor Signaling WP581,0.2916398988241153,0.9040922083958527,0.6428571428571429,0.9407388418302507,1.0,5/26,16.62%,MAP2K1;SOS1;STAT1;STAT5B;MAPK1
gsea,Zinc homeostasis WP3529,0.3192818508400852,0.9008753646124843,0.5686274509803921,0.9422072999025236,1.0,8/36,32.12%,SLC39A14;SLC39A8;MT1A;SLC39A9;SLC30A9;SLC30A5;SLC39A10;MT1E
gsea,Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling WP3850,0.27495731411408175,0.9005937564684445,0.6,0.9362992595938251,1.0,8/37,29.18%,EIF4E;WASL;ITGB1;GSK3B;MTOR;JKAMP;RPTOR;RICTOR
gsea,Nucleotide-binding Oligomerization Domain (NOD) pathway WP1433,-0.3044498212625079,-0.8993446573451901,0.6595744680851063,1.0,1.0,3/41,6.41%,AAMP;NDUFA13;PYCARD
gsea,EGF/EGFR signaling pathway WP437,0.21019964971380356,0.8970499828529049,0.6046511627906976,0.9384510245704706,1.0,45/162,31.62%,PCNA;E2F1;MYBL2;PRKCI;IQGAP1;USP6NL;MAP2K1;SOS1;JAK1;STAMBP;USP8;IQSEC1;PTPN11;STAT1;RALB;CRK;MAP3K2;STAT5B;MAPK1;ROCK1;STAM;DNM1;CREB1;PDPK1;RPS6KA3;AURKA;AP2B1;PLSCR1;KRAS;MAPK8;CRKL;MTOR;RAP1A;ATXN2;RAF1;CSK;ERRFI1;RICTOR;EPS15;RAB5A;RALBP1;NEDD4;PTK2;SH2D2A;SP1
gsea,Interleukin-11 Signaling Pathway WP2332,0.26844293014892917,0.8930875662903953,0.6666666666666666,0.9403818319663656,1.0,12/44,29.90%,MAP2K1;JAK1;PTPN11;PIAS1;STAT1;BIRC5;MAPK1;CREB1;PDPK1;RAF1;IL6ST;CHUK
gsea,NRF2-ARE regulation WP4357,0.2651006461767379,0.8914266520731403,0.6226415094339622,0.9380212282031842,1.0,10/23,33.39%,GCLM;SLC7A11;AIMP2;NFE2L2;GSK3B;MAPK8;HMOX1;PIK3CA;EPHB2;RBX1
gsea,Regulation of apoptosis by parathyroid hormone-related protein WP3872,-0.27907631862101206,-0.8896095699323676,0.6181818181818182,1.0,1.0,5/22,17.05%,BAX;BOK;BCL2L2;BAK1;MYC
gsea,IL-6 signaling pathway WP364,0.26044080707530115,0.8809337920365282,0.6666666666666666,0.9570573318344618,1.0,10/43,25.81%,MAP2K4;MAP2K1;SOS1;JAK1;PTPN11;STAT1;MAPK1;GSK3B;NLK;TIMP1
gsea,Fatty Acid Biosynthesis WP357,0.4073413495396259,0.8792056460284966,0.7843137254901961,0.9542409671087477,1.0,12/22,40.18%,PC;ACSL3;HADH;FASN;SCD;ACACA;ECHDC1;ACSL5;ACLY;ACSL4;ACSL1;ACSS2
gsea,Pathways Regulating Hippo Signaling WP4540,0.25591524275307626,0.8745915146859875,0.5740740740740741,0.9580541845244541,1.0,12/98,24.04%,PRKCI;RHOA;STK3;GNAQ;GNAS;TCF7;PRKACB;PRKAA1;PRKAR2A;CDH1;TEAD4;MTOR
gsea,EGFR Tyrosine Kinase Inhibitor Resistance WP4806,-0.2378779280560942,-0.8727456940577315,0.68,1.0,1.0,15/84,17.50%,GAS6;PIK3CD;MAPK3;EGFR;ERBB2;BAX;RRAS;PDGFC;MAP2K2;EIF4E2;PDGFB;AKT2;BAD;MYC;IL6
gsea,FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma WP4553,0.26138399229210113,0.8715845483900343,0.7,0.958219781570805,1.0,4/35,16.62%,SUZ12;EZH2;H2AFX;MAPK1
gsea,Adipogenesis WP236,-0.20889498468529502,-0.8692592966102398,0.8695652173913043,1.0,1.0,16/130,17.50%,GADD45A;ENST00000634790.2;NR1H3;LMNA;KLF15;CELF1;IRS2;GADD45B;STAT2;CEBPB;BMP1;DVL1;STAT6;CEBPD;AGPAT2;IL6
gsea,Pre-implantation embryo WP3527,-0.3084104848540624,-0.8683453044814023,0.6458333333333334,1.0,1.0,10/58,24.02%,ESRRA;FOXQ1;ZFP36;BARX2;SMARCA4;PBX1;DDIT3;ZFP36L2;MTA3;AQP3
gsea,Structural Pathway of Interleukin 1 (IL-1) WP2637,-0.25336124726368353,-0.866274309612634,0.6538461538461539,1.0,1.0,9/49,17.05%,TOLLIP;MAPK3;MAPKAPK2;TAB1;MAP2K2;TAB2;MAPK14;MAPK11;MYC
gsea,Host-pathogen interaction of human coronaviruses - MAPK signaling WP4877,-0.26564089542843583,-0.8659804562949541,0.5869565217391305,1.0,1.0,8/36,16.25%,MAPK3;JUNB;MAP3K11;MAP2K2;MAPK13;MAPK14;IFITM1;MAPK11
gsea,IL-3 signaling pathway WP286,0.24771283200484576,0.8649089632117198,0.7346938775510204,0.965801832789738,1.0,11/49,26.80%,MAP2K1;SOS1;JAK1;PTPN11;STAT5B;MAPK1;YWHAB;MAPK8;CRKL;YWHAQ;RAF1
gsea,Nanoparticle-mediated activation of receptor signaling WP2643,0.2545260154509556,0.8626214333991592,0.625,0.9640940106141017,1.0,9/28,23.39%,FN1;MAP2K1;SOS1;MAPK1;ITGB1;NRAS;MAPK12;KRAS;MAPK8
gsea,Microglia Pathogen Phagocytosis Pathway WP3937,-0.2818740313665307,-0.8593869727437167,0.68,1.0,1.0,2/40,3.52%,PTPN6;PIK3CD
gsea,IL-7 signaling pathway WP205,0.28185351573375095,0.8559387150633613,0.7777777777777778,0.9718982371754641,1.0,5/25,16.62%,MAP2K1;JAK1;STAT1;STAT5B;MAPK1
gsea,Translation Factors WP107,0.21540195778898397,0.8525706089079473,0.8292682926829268,0.9734946729978851,1.0,17/52,30.18%,EIF5B;EIF2S2;EIF4E;EIF3CL;EIF1AX;EIF2S1;EIF2AK2;EIF4H;EIF3E;EIF2S3;EIF4G3;EIF2B1;PABPC1;EIF4G1;ENST00000630137.2;ETF1;EIF2AK1
gsea,Signal transduction through IL1R WP4496,-0.29750305441322206,-0.8514409733420177,0.6140350877192983,1.0,1.0,6/33,24.62%,TOLLIP;TAB1;MAPK14;IL6;NFKBIA;ECSIT
gsea,Novel intracellular components of RIG-I-like receptor (RLR) pathway WP3865,-0.2687457486173609,-0.8506019977748868,0.673469387755102,1.0,1.0,12/60,23.91%,TRADD;TKFC;MAPK13;MAPK14;MAPK11;DDX17;OTUD5;RIPK1;TRAF2;MAVS;NFKBIA;FADD
gsea,Head and Neck Squamous Cell Carcinoma WP4674,0.2255732963359142,0.8494131617168272,0.64,0.9729295812335548,1.0,19/73,29.18%,E2F1;EIF4E;CDK6;FAT1;PIK3CB;FKBP1A;RB1;NRAS;NOTCH1;PRKAA1;VEGFA;PDPK1;NFE2L2;KRAS;MTOR;RPS6KB2;RPTOR;PIK3CA;RICTOR
gsea,"Non-genomic actions of 1,25 dihydroxyvitamin D3 WP4341",-0.21980769699299188,-0.8482237262099336,0.775,1.0,1.0,11/71,21.97%,RELB;MAPK3;STAT2;MAPK13;MAPK14;MAPK11;PRKCZ;IL6;IFI27L2;NFKB2;PRKCG
gsea,B Cell Receptor Signaling Pathway WP23,0.22091465931461185,0.8480149815613683,0.6862745098039216,0.96944753502752,1.0,14/97,23.69%,ILF2;MAP2K1;SOS1;BCL10;PTPN11;CRK;PIP5K1A;MAPK1;E2F3;CREB1;PDPK1;GSK3B;MAPK8;CRKL
gsea,nsp1 from SARS-CoV-2 inhibits translation initiation in the host cell WP5027,0.2722269244311379,0.8468791626723542,0.7380952380952381,0.9653941157768593,1.0,6/17,22.71%,EIF2S2;EIF3CL;EIF1AX;EIF2S1;EIF3E;EIF2S3
gsea,Wnt signaling WP428,0.22667923444118918,0.846862004480809,0.7142857142857143,0.9592931708170527,1.0,15/115,24.41%,RYK;PPP3R1;CTBP2;CCND3;ROCK2;VANGL1;CSNK1E;DAAM1;RHOA;TCF7;SFRP1;GSK3B;CTNNBIP1;MAPK8;NLK
gsea,Alpha 6 Beta 4 signaling pathway WP244,0.28485920140302107,0.8441433420928114,0.6538461538461539,0.9594413834066533,1.0,10/33,25.39%,SOS1;PTPN11;LAMC1;RHOA;MAPK1;ITGA6;ITGB4;MTOR;LAMA5;LAMA3
gsea,Small cell lung cancer WP4658,0.2305854336424602,0.8423535108004392,0.7090909090909091,0.957082945461176,1.0,19/96,25.64%,CDK2;E2F1;FN1;CDK6;PIK3CB;DDB2;LAMC1;RB1;CKS1B;ITGB1;ITGA6;ITGA3;E2F3;BID;SKP1;CYCS;LAMA5;LAMA3;CCNE1
gsea,PPAR signaling pathway WP3942,0.2738673112387532,0.8404800822372094,0.7407407407407407,0.9562132547527429,1.0,15/67,39.09%,ME1;ACSL3;FABP5;SCD;PDPK1;PPARD;ACADM;PPARA;SLC27A4;ACSL5;FADS2;PPARG;ACOX3;ACSL4;ACSL1
gsea,Synaptic signaling pathways associated with autism spectrum disorder WP4539,0.23149952197446735,0.8356464938164807,0.7954545454545454,0.9599601971190296,1.0,10/50,27.91%,SYNGAP1;PIK3CB;MAPK1;NRAS;PRKAA1;GSK3B;KRAS;MTOR;RPTOR;PIK3CA
gsea,LncRNA involvement in canonical Wnt signaling and colorectal cancer WP4258,0.23451571835171475,0.8347035305713498,0.6875,0.955777716037465,1.0,13/94,24.41%,RYK;CTBP2;CCND3;CDK6;CSNK1E;EZH2;CDK8;HNRNPU;TCF7;SFRP1;GSK3B;CTNNBIP1;NLK
gsea,Parkinson's disease pathway WP2371,0.2640144805378115,0.8304919974135306,0.6521739130434783,0.9574593547300143,1.0,10/38,26.67%,UCHL1;EPRS;UBA1;CASP2;PARK7;UBE2G1;MAPK12;CYCS;CCNE1;ATXN2
gsea,Initiation of transcription and translation elongation at the HIV-1 LTR WP3414,-0.28687933013497713,-0.8299023422117189,0.7115384615384616,1.0,1.0,13/32,30.60%,NELFB;HDAC5;NFATC3;HEXIM1;HDAC7;NELFE;HDAC8;NELFA;NFKBIA;PPP3CA;SUPT5H;HDAC4;CDK9
gsea,Type II interferon signaling (IFNG) WP619,0.3048175109441288,0.8286237104166094,0.6938775510204082,0.9553528653888194,1.0,5/37,18.84%,IRF2;JAK1;PTPN11;STAT1;EIF2AK2
gsea,Toll-like Receptor Signaling Pathway WP75,-0.22881875646539526,-0.8278806472845364,0.6122448979591837,1.0,1.0,12/103,17.50%,TICAM1;TOLLIP;PIK3CD;MAPK3;TAB1;MAP2K2;TAB2;MAPK13;MAPK14;MAPK11;AKT2;IL6
gsea,Lipid Metabolism Pathway WP3965,-0.2523039712492561,-0.8266386448011028,0.7,1.0,1.0,6/29,17.72%,HILPDA;ABHD5;PNPLA2;PRKAG1;AKT2;BCKDHA
gsea,Netrin-UNC5B signaling pathway WP4747,0.24633613224760165,0.8258219283440509,0.68,0.9555187780839143,1.0,11/52,27.91%,MAP2K1;PPP1CA;PPP2R1B;CIP2A;PTPN11;RHOA;MAPK1;ITGB4;RLF;RAF1;PIK3CA
gsea,T-cell receptor (TCR) signaling pathway WP69,0.22158795367309436,0.8248938145226915,0.7872340425531915,0.952208973740437,1.0,13/90,27.01%,MAP2K1;SOS1;BCL10;PTPN11;CRK;MAPK1;RIPK2;CREB1;PDPK1;MAPK8;CRKL;RAF1;CD83
gsea,Non-small cell lung cancer WP4255,0.2333410126488052,0.823711910564597,0.7924528301886793,0.9486102103638208,1.0,17/72,23.29%,E2F1;MAP2K1;CDK6;STK4;SOS1;PIK3CB;DDB2;STAT5B;MAPK1;RB1;EML4;NRAS;E2F3;CRABP2;BID;CYCS;KRAS
gsea,FGFR3 signaling in chondrocyte proliferation and terminal differentiation WP4767,0.29636833286422454,0.8213366735230511,0.6949152542372882,0.9466888815242902,1.0,6/27,20.54%,MAP2K1;PPP2CA;STAT1;MAPK1;BMP4;MAPK12
gsea,Nanoparticle triggered autophagic cell death WP2509,0.29602387868112334,0.8201914006750904,0.7959183673469388,0.9430033575219322,1.0,3/23,12.02%,ATG3;CHAF1A;ATG4A
gsea,TGF-beta Receptor Signaling WP560,-0.21681715984016398,-0.8198083910593892,0.8043478260869565,1.0,1.0,5/54,12.03%,MAPK3;BAMBI;SKIL;SMAD7;THBS1
gsea,Energy Metabolism WP1541,0.2494577219781924,0.8148451593600128,0.6739130434782609,0.9467904230836521,1.0,9/47,25.17%,PPP3R1;GABPA;PRMT1;TFAM;PRKAA1;CREB1;GSK3B;PPARD;MYBBP1A
gsea,Interferon type I signaling pathways WP585,0.22871876256378368,0.8136823293235097,0.7317073170731707,0.9429068367301431,1.0,13/54,25.16%,EIF4E;JAK1;RPS6KA4;PRMT1;PTPN11;PIAS1;STAT1;CRK;CREB1;IFNAR1;CRKL;MTOR;RAP1A
gsea,p38 MAPK Signaling Pathway WP400,-0.24691247719341827,-0.8119484887379163,0.7608695652173914,1.0,1.0,9/34,23.37%,TRADD;MAPKAPK2;MAPK14;MYC;RIPK1;DDIT3;TRAF2;RASGRF1;GRB2
gsea,Host-pathogen interaction of human coronaviruses - interferon induction WP4880,0.27345580837205796,0.8108650483776458,0.7560975609756098,0.9413032201428514,1.0,7/33,23.39%,OAS3;JAK1;TBK1;STAT1;EIF2AK2;IFNAR1;MAPK8
gsea,T-Cell Receptor and Co-stimulatory Signaling WP2583,-0.2790874355615054,-0.8100628677907533,0.6808510638297872,1.0,1.0,5/29,24.33%,PTPN6;DYRK2;RASA1;NFKBIA;PPP3CA
gsea,Melanoma WP4685,0.22125325519193192,0.8098687709892796,0.803921568627451,0.9374173528219053,1.0,14/68,23.29%,E2F1;MAP2K1;CDK6;SOS1;PIK3CB;DDB2;VCL;MAPK1;RB1;NRAS;E2F3;CREB1;CDH1;KRAS
gsea,Focal Adhesion WP306,0.1996801557200578,0.8098651798103279,0.7551020408163265,0.9319987554067497,1.0,37/198,28.16%,ARHGAP5;FN1;PPP1CC;CCND3;MAP2K1;ROCK2;SOS1;PPP1CA;PIK3CB;DIAPH1;RAP1B;VCL;CRK;LAMC1;RHOA;MAPK1;ITGB1;ROCK1;ITGA6;ITGA3;VEGFA;ITGB4;PPP1R12A;PDPK1;GSK3B;MAPK8;CRKL;PAK2;LAMA5;RAP1A;LAMA3;SPP1;RAF1;FLNB;FLNA;PIK3CA;ITGA5
gsea,Kisspeptin/kisspeptin receptor system in the ovary WP4871,-0.249649802354939,-0.8070828643010844,0.7906976744186046,1.0,1.0,6/39,16.62%,PIK3CD;MAPK3;MAP2K2;ARRB2;AKT2;ARRB1
gsea,Metapathway biotransformation Phase I and II WP702,-0.2481203264964311,-0.8011314956050607,0.723404255319149,1.0,1.0,20/183,29.01%,GPX4;GSTZ1;NDST2;NDST1;NAT14;COMT;MGST2;MGST3;AKR1B1;NAA50;UGT1A6;GSTP1;HS6ST1;CHST12;GSS;SULT1A1;HS3ST1;GSTK1;AKR1C1;NAA20
gsea,Kit receptor signaling pathway WP304,0.2050466548778822,0.7988989316485128,0.8431372549019608,0.9453086193824998,1.0,11/59,23.69%,MAP2K1;SOS1;KITLG;PTPN11;STAT1;CRK;STAT5B;MAPK1;RPS6KA3;MAPK8;CRKL
gsea,Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway WP2203,-0.23694628604558635,-0.7979783007867867,0.7962962962962963,1.0,1.0,11/47,23.74%,RELB;MAPK3;YES1;MAP2K2;MAPK14;STAT6;MYC;IL6;NFKB2;GAB2;NFKBIA
gsea,Vitamin B12 metabolism WP1533,-0.2459340934022763,-0.7871852030787734,0.7916666666666666,1.0,1.0,8/50,33.61%,TCN2;IL6;NFKB2;ICAM1;SAA2;SERPINE1;PLAT;MTRR
gsea,Pancreatic adenocarcinoma pathway WP4263,0.19995295637955715,0.7869802860324568,0.8333333333333334,0.9608058052637278,1.0,24/89,31.46%,E2F1;MAP2K1;CDK6;JAK1;PIK3CB;DDB2;STAT1;RALB;RAD51;RHOA;MAPK1;RB1;VEGFA;E2F3;KRAS;MAPK8;MTOR;PAK2;RPS6KB2;RAF1;PIK3CA;CHUK;RALBP1;CDK4
gsea,IL-1 signaling pathway WP195,-0.21918656142431725,-0.784390275767737,0.7954545454545454,1.0,1.0,12/55,24.62%,TOLLIP;MAPK3;MAPKAPK2;TAB1;MAP2K2;TAB2;MAPK14;PRKCZ;PELI1;NFKBIA;TAB3;ECSIT
gsea,Brain-derived neurotrophic factor (BDNF) signaling pathway WP2380,0.1806249251628544,0.782517159611741,0.84,0.962635260872562,1.0,23/144,25.50%,EIF2S2;EIF4E;ADAM17;MAP2K1;PPP2CA;PTPN11;STAT1;EIF2S1;MAP3K2;STAT5B;MAPK1;DPYSL2;PRKAA1;CREB1;PDPK1;RPS6KA3;RANBP9;GSK3B;MAPK8;CYFIP1;MTOR;RAP1A;SPP1
gsea,Neural Crest Differentiation WP2064,0.21502789090430388,0.7796863230063728,0.8771929824561403,0.9618997442849616,1.0,10/101,22.91%,CTBP2;ID1;HDAC3;ITGB1;BMP4;NOTCH1;HDAC2;CDH1;RBPJ;GSK3B
gsea,AGE/RAGE pathway WP2324,-0.21433107461195572,-0.7764590613441668,0.7959183673469388,1.0,1.0,5/66,6.07%,MMP14;FOXO4;MAPK3;LGALS3;EGFR
gsea,Senescence and Autophagy in Cancer WP615,-0.19557743372365444,-0.7739089600200286,0.76,1.0,1.0,19/105,20.80%,GSN;MMP14;RSL1D1;AKT1S1;ENST00000642871.1;CDKN2A;IFI16;THBS1;ATG13;GABARAPL1;CEBPB;MAPK14;SLC39A3;IL6;ATG14;SMAD4;GABARAP;LAMP2;LAMP1
gsea,Acute viral myocarditis WP4298,-0.21086697031103924,-0.7722486868904005,0.7547169811320755,1.0,1.0,6/86,8.21%,CASP6;KRT8;TICAM1;MAPK3;PYCARD;BAX
gsea,Cell migration and invasion through p75NTR WP4561,-0.2715499694070016,-0.7702617583110487,0.8,1.0,1.0,4/30,20.69%,TRIO;EFNA4;AKT2;EFNA1
gsea,Hepatitis B infection WP4666,0.19542607413956062,0.7688772309420014,0.7692307692307693,0.9735925241287663,1.0,23/152,23.39%,PCNA;MAP2K4;VDAC3;MAP2K1;SOS1;JAK1;PIK3CB;DDB2;YWHAZ;TBK1;STAT1;BIRC5;STAT5B;MAPK1;NRAS;YWHAB;MAPK12;BID;CREB1;IFNAR1;CYCS;KRAS;MAPK8
gsea,Follicle Stimulating Hormone (FSH) signaling pathway WP2035,0.2579942679948291,0.760882594587988,0.8727272727272727,0.9806565834113367,1.0,7/27,26.80%,GRK6;APPL1;MAPK1;CREB1;MTOR;RPS6KB2;RAF1
gsea,Immune response to tuberculosis WP4197,0.29723812573220293,0.7592709834380126,0.7333333333333333,0.9771796815769522,1.0,5/23,22.13%,JAK1;PIAS1;STAT1;PTPN2;IFNAR1
gsea,Ras signaling WP4223,0.18339799130707576,0.7541464528684246,0.9361702127659575,0.9797728900598562,1.0,31/184,29.90%,MAP2K1;STK4;SOS1;SYNGAP1;PIK3CB;ETS2;RAP1B;PTPN11;RALB;GNG12;PLA2G12A;RHOA;MAPK1;NRAS;GNB4;PRKACB;EXOC2;BRAP;SHOC2;KRAS;RASGRP1;MAPK8;RASAL2;RAB5C;PAK2;RAP1A;RAF1;PIK3CA;RAB5B;RAB5A;CHUK
gsea,Calcium Regulation in the Cardiac Cell WP536,0.24070242517371207,0.7537166668327044,0.7450980392156863,0.9752893050846045,1.0,15/150,21.30%,YWHAE;YWHAH;ATP1B3;GRK6;FKBP1A;YWHAZ;ADCY3;GNG12;ATP1B1;GNAQ;GNAS;GNB4;PRKACB;YWHAB;PRKAR2A
gsea,Unfolded protein response WP4925,0.2551572341548279,0.7506537648104831,0.8604651162790697,0.9743596117277122,1.0,8/24,24.99%,CASP2;HSPA5;EIF2S1;RTCB;XBP1;BID;NFE2L2;MBTPS2
gsea,Serotonin Receptor 2 and ELK-SRF/GATA4 signaling WP732,-0.2507427901417893,-0.7494344809398994,0.8222222222222222,1.0,1.0,4/20,12.77%,MAPK3;MAPKAPK2;SRF;MAP2K2
gsea,Intraflagellar transport proteins binding to dynein WP4532,0.24657501432945766,0.7484710739865736,0.8695652173913043,0.9726983551438837,1.0,4/27,22.03%,DYNC1LI1;DYNC1I2;IFT122;WDR34
gsea,Tumor suppressor activity of SMARCB1 WP4204,0.23166935079021167,0.7462831797297858,0.8163265306122449,0.9703911644775935,1.0,6/31,23.32%,SUZ12;CDK6;EZH2;RB1;SMARCD1;DPF2
gsea,Heart Development WP1591,0.2322363950455649,0.7461562318545687,0.8269230769230769,0.9654674851427033,1.0,5/44,19.01%,PTPN11;MAPK1;BMP4;NOTCH1;VEGFA
gsea,Ciliopathies WP4803,0.18818362020684395,0.7458596256349426,0.8571428571428571,0.9611073045939031,1.0,17/183,23.94%,CENPF;NEK2;PLK4;ARL2BP;TMEM138;MKKS;OFD1;PIK3R4;CFAP298;TMEM107;IFT122;ANKS6;IFT57;TCTN3;WDR34;TCTN1;CEP78
gsea,Wnt Signaling Pathway WP363,0.21280462719976087,0.7448910255366993,0.8723404255319149,0.9572290419886117,1.0,9/52,24.41%,RYK;CDK6;CSNK1E;RHOA;MAPK1;GSK3B;MAPK8;MTOR;NLK
gsea,Notch Signaling Pathway Netpath WP61,0.19674279872396616,0.7427405192757252,0.94,0.9551247337449006,1.0,10/61,23.86%,ADAM17;NOTCH1;HDAC2;SNW1;HIF1A;SKP1;RBPJ;GSK3B;SPEN;CUL1
gsea,p53 transcriptional gene network WP4963,0.20668118564333515,0.7419442047043919,0.9,0.9508878336858066,1.0,9/67,19.51%,XRCC5;SLC7A11;MSH2;ERCC5;DDB2;FANCC;ADORA2B;NOTCH1;SERPINB5
gsea,MAPK Signaling Pathway WP382,-0.18637392954306,-0.7416947874761541,0.8431372549019608,1.0,1.0,39/246,24.62%,GADD45A;RAPGEF2;RELB;MAPK3;JUND;MAPKAPK2;TAOK2;EGFR;NFATC3;TAB1;RRAS;NTF4;MAP3K11;SRF;DUSP1;MAPK8IP3;MAP2K2;TAB2;CACNB3;MAPK13;ARRB2;MAPK14;PDGFB;MAPK11;AKT2;ARRB1;MYC;MAP4K4;DUSP3;DDIT3;RASA1;TRAF2;NFKB2;PRKCG;RASGRF1;GRB2;CDC25B;PPP3CA;ECSIT
gsea,Splicing factor NOVA regulated synaptic proteins WP4148,-0.26782550854367415,-0.7357652449529546,0.9148936170212766,1.0,1.0,6/42,19.38%,MAP4;NCDN;AGRN;APLP2;PRKCZ;ATP2B1
gsea,Breast cancer pathway WP4262,0.18227846365146952,0.7351894967072412,0.8793103448275862,0.9561979764139896,1.0,32/154,33.27%,BRCA1;E2F1;PARP1;MAP2K1;CDK6;SOS1;DDB2;RAD51;MAPK1;RB1;TCF7;CETN3;NRAS;NOTCH1;RAD50;E2F3;SKP1;GSK3B;KRAS;MTOR;ATR;RPS6KB2;RAF1;PIK3CA;NOTCH3;HES1;CDK4;SP1;NBN;CSNK1A1;NOTCH2;RPS6KB1
gsea,TYROBP causal network in microglia WP3945,0.24119564082335976,0.7329492651176095,0.8604651162790697,0.9549137604245641,1.0,6/61,17.16%,DPYD;FKBP15;ELF4;SLC1A5;PPP1R18;IL13RA1
gsea,Ebola Virus Pathway on Host WP4217,-0.19420149810973017,-0.7308030291543101,0.8,1.0,1.0,12/129,11.25%,GSN;GAS6;CLTB;RELB;PIK3CD;MAPK3;EGFR;VPS18;MFGE8;ACTG1;HLA-C;RHOB
gsea,TGF-beta receptor signaling in skeletal dysplasias WP4816,-0.1887310298538677,-0.72678842813888,0.9166666666666666,1.0,1.0,5/58,12.03%,MAPK3;BAMBI;SKIL;SMAD7;THBS1
gsea,Regulatory circuits of the STAT3 signaling pathway WP4538,-0.208738095232603,-0.7217998123444778,0.8703703703703703,1.0,1.0,8/78,17.14%,MAPK3;EGFR;AKT1S1;TRIM28;MAPK13;MAPK14;MAPK11;CTF1
gsea,Osteoblast differentiation WP4787,0.1706020356211371,0.715909977899253,0.92,0.9718855939693676,1.0,13/118,23.39%,PRKDC;PRKCI;PIK3CB;PIK3C3;STAT1;PIK3R4;MAPK1;BMP4;NOTCH1;PIK3C2A;MAPK12;RBPJ;MAPK8
gsea,SARS-CoV-2 mitochondrial interactions WP5038,-0.28063004927592106,-0.7128384464540727,0.7906976744186046,1.0,1.0,7/32,27.37%,TICAM1;NDUFB9;NDUFAF1;NFKB2;MAVS;ECSIT;CTSL
gsea,Oxidative Stress WP408,-0.2255110732538226,-0.7127745920568997,0.7959183673469388,1.0,1.0,20/33,77.51%,JUNB;CAT;MAPK14;UGT1A6;NQO1;GPX1;TXNRD2;MT1X;GCLC;GPX3;NFIX;TXNRD1;TXN2;GSR;SOD2;SP1;SOD1;MGST1;HMOX1;NFE2L2
gsea,Selenium Micronutrient Network WP15,-0.2089292535686746,-0.7123592666938977,0.9230769230769231,1.0,1.0,11/89,21.53%,GPX4;PRDX5;SELENOH;CAT;GGT1;SELENOO;PTGS2;IL6;SEPHS2;SELENOS;NFKB2
gsea,Fatty acid beta-oxidation WP143,0.22913858812284832,0.7091487752913029,0.7872340425531915,0.9745433513361419,1.0,8/34,29.46%,ACSL3;HADHA;HADH;TPI1;GPD2;DLD;ACAT1;ACADM
gsea,Aryl Hydrocarbon Receptor Pathway WP2873,-0.2038311408137875,-0.7039492205566326,0.9433962264150944,1.0,1.0,5/46,8.21%,JUND;JUNB;EGFR;AHRR;BAX
gsea,ncRNAs involved in Wnt signaling in hepatocellular carcinoma WP4336,0.19628078457135995,0.7032370742951308,0.86,0.9764040356913746,1.0,11/86,24.41%,RYK;CTBP2;CCND3;CSNK1E;EZH2;ELAVL1;TCF7;SFRP1;GSK3B;CTNNBIP1;NLK
gsea,Arrhythmogenic Right Ventricular Cardiomyopathy WP2118,-0.2195120561878308,-0.6988589974750381,0.8461538461538461,1.0,1.0,6/74,14.28%,LMNA;ATP2A2;JUP;ACTG1;CACNB3;DAG1
gsea,Nuclear Receptors Meta-Pathway WP2882,-0.15274300684741923,-0.6984864981127611,0.9795918367346939,1.0,1.0,35/319,18.67%,NR1H3;ENC1;SCNN1A;S100P;CBR1;JUND;JUNB;FTH1;EGFR;AHRR;BAX;GGT1;MFGE8;IRS2;SLC27A1;ENST00000642871.1;PTGR1;SLC5A6;GCC1;PLTP;ABHD2;GADD45B;MGST2;MGST3;ETNK2;PDGFB;CBR3;SLC39A3;MYC;CES2;PTGS2;CPT1A;MYOF;CDC37;PRDX6
gsea,Chromosomal and microsatellite instability in colorectal cancer  WP4216,0.19106419085503173,0.6974942739065934,0.9433962264150944,0.9782457334715539,1.0,15/73,23.39%,MSH2;MAP2K1;DDB2;APPL1;TBK1;RALB;BIRC5;RHOA;MAPK1;TCF7;EXOC2;CYCS;GSK3B;KRAS;MAPK8
gsea,Complement system WP2806,-0.22218970442281724,-0.6970807518248744,0.8974358974358975,1.0,1.0,11/97,28.76%,FKBP2;CD59;THBS1;C1R;ARRB2;C1S;ADM;ICAM1;C3;LAMB1;GNA15
gsea,Bladder cancer WP2828,-0.22322499430601012,-0.6941970689537041,0.9090909090909091,1.0,1.0,8/40,17.05%,EGFR;ERBB2;DAPK2;CDKN2A;THBS1;MAP2K2;DAPK3;MYC
gsea,Spinal Cord Injury WP2431,-0.19622802248746335,-0.6884815842787894,0.9791666666666666,1.0,1.0,6/118,6.62%,GADD45A;CCNG1;MAPK3;LGALS3;EGFR;ZFP36
gsea,Insulin Signaling WP481,0.16462540048760038,0.6873605925953141,0.9555555555555556,0.98457145276186,1.0,28/160,25.71%,MAP2K4;PRKCI;EIF4E;MAP2K1;KIF5B;SOS1;TBC1D4;MAP4K5;PIK3CB;RPS6KA4;PTPN11;PIK3C3;CRK;PIK3R4;MAP3K2;MAPK1;PRKAA1;XBP1;PIK3C2A;MAPK12;PDPK1;RPS6KA3;GSK3B;MAPK8;MTOR;MAPK6;RPS6KB2;SLC2A1
gsea,Prostaglandin Synthesis and Regulation WP98,0.2438505362156434,0.6827844783697481,0.9411764705882353,0.9847680749879385,1.0,1/45,0.17%,ANXA5
gsea,ErbB signaling pathway WP673,0.1876502388755693,0.6818100721601597,0.9183673469387755,0.98071098479509,1.0,18/91,27.91%,MAP2K4;MAP2K1;SOS1;PIK3CB;CRK;STAT5B;MAPK1;NRAS;PDPK1;GSK3B;KRAS;MAPK8;CRKL;MTOR;PAK2;RPS6KB2;RAF1;PIK3CA
gsea,Overview of leukocyte-intrinsic Hippo pathway functions WP4542,-0.20357424890338455,-0.6769442178347884,0.9482758620689655,1.0,1.0,5/35,15.86%,FOXO4;RAB13;VMP1;MAPK14;TEAD3
gsea,Ectoderm Differentiation WP2858,-0.16539255919969026,-0.6752571454793665,1.0,1.0,1.0,12/138,18.13%,AES;SERPINB6;SKIL;ZNF219;JUP;STX16;FHL2;GATA6;ZBTB7B;GLB1;MYC;SMAD4
gsea,IL-18 signaling pathway WP4754,-0.16477324711004637,-0.6743439598185426,0.9787234042553191,1.0,1.0,54/272,29.44%,TMSB4X;NR1H3;MMP14;HPS1;NACA;STK40;MAPK3;USP5;ARFGAP1;CFLAR;GRN;BAX;ZNF219;ZNF444;CCDC9;EEF2;IMP3;CLDN4;CEBPB;GPAT4;PHF20;PTMS;ZBTB7A;IRF6;ZDHHC7;BAD;PTGS2;CPT1A;SDC4;IL6;COX17;ECH1;ATF3;NFKB2;B2M;PPP1R13L;CLDN12;NFKBIA;FADD;ABCF1;CASP3;IL18;HSPB8;PYGB;IRF1;ICAM1;BPGM;RAE1;TP53;CTNNB1;CLDN3;IL17RC;TIMP3;PLCG1
gsea,Prolactin Signaling Pathway WP2037,0.16614261624560353,0.6735713798111103,0.9259259259259259,0.9846777862016679,1.0,16/76,27.91%,MAP2K1;SOS1;JAK1;PIK3CB;YWHAZ;PTPN11;STAT1;STAT5B;MAPK1;ITGB1;GSK3B;MAPK8;MTOR;RAF1;FLNA;PIK3CA
gsea,IL-4 signaling pathway WP395,-0.2063977032594448,-0.6640282756219632,0.9272727272727272,1.0,1.0,9/54,16.72%,PTPN6;PIK3CD;MAPK3;IRS2;CEBPB;MAPK14;MAPK11;STAT6;BAD
gsea,Signal Transduction of S1P Receptor WP26,0.21278710949695723,0.6634741522925199,0.9464285714285714,0.9875188123069263,1.0,5/25,25.33%,RACGAP1;MAPK1;S1PR3;MAPK12;MAPK6
gsea,Copper homeostasis WP3286,-0.1962109171797767,-0.661380481711723,0.9285714285714286,1.0,1.0,6/52,14.52%,SLC31A2;CCS;APP;COX11;STEAP3;COMMD1
gsea,22q11.2 copy number variation syndrome WP4657,0.19074998878048482,0.6588100295488589,0.8703703703703703,0.9864809073780767,1.0,21/131,31.63%,PLK1;XPO1;DGCR8;CBX5;RAN;HDAC3;CDC45;ASF1A;PI4KA;RTN4;SHOC2;RANBP1;TANGO2;CRKL;RAF1;TNPO1;KPNB1;HIST1H4I;SNAP29;HES1;THAP7
gsea,Cannabinoid receptor signaling WP3869,-0.22874621057421066,-0.6555439422098884,0.9555555555555556,1.0,1.0,6/29,24.37%,MAPK3;MAPK13;MAPK14;MAPK11;ADCY7;FAAH
gsea,Myometrial relaxation and contraction pathways WP289,-0.16597941507268912,-0.6535462485644328,0.9787234042553191,1.0,1.0,15/156,17.50%,PKIG;RGS10;DGKZ;ATP2A2;IGFBP6;ATF6B;ACTG1;CALD1;CNN2;CACNB3;ARRB2;ARRB1;PRKCZ;ADCY6;IL6
gsea,ESC Pluripotency Pathways WP3931,-0.176099094889616,-0.6481554130500898,0.9591836734693877,1.0,1.0,21/116,29.93%,PIK3CD;EGFR;WNT5A;DVL2;SMAD7;MAP2K2;DVL1;PDGFB;AKT2;SMAD4;FZD7;DVL3;WNT5B;GRB2;FZD2;WNT6;WNT7B;CTNNB1;NOG;WNT10A;LRP5
gsea,Proximal tubule transport WP4917,0.2227274390814836,0.6428136456653089,0.8913043478260869,0.9929152179027999,1.0,11/57,35.58%,ABCC2;SLC3A2;ATP6V1C1;ATP1B1;ATP1A1;ATP6V0E1;SLC2A1;ABCC4;ATP6V1E1;ATP6V1D;ATP6V1A
gsea,Fragile X Syndrome  WP4549,0.17019325179895242,0.6422141018361769,0.9791666666666666,0.9887169424251885,1.0,21/121,27.70%,ABCD3;EIF4E;TECR;MAP2K1;SOS1;SYNGAP1;PPP1CA;PIK3CB;DNM2;PTPN11;MAPK1;ENST00000630362.2;DNM1;CREB1;AP2B1;KRAS;CYFIP1;MTOR;RAF1;EIF4G1;RPTOR
gsea,Thermogenesis WP4321,-0.153928193428655,-0.6395195738766624,1.0,1.0,1.0,17/108,24.56%,ACTL6A;PNPLA2;AKT1S1;ACTG1;SMARCC1;PRKAG1;MAPK13;MAPK14;MAPK11;SMARCA4;CPT1A;ADCY6;TSC2;KDM3B;GRB2;ADCY7;SMARCD2
gsea,Cardiac Hypertrophic Response WP2795,0.17510010264455705,0.6370261558526217,0.9777777777777777,0.9875552432552377,1.0,18/55,41.35%,MAP2K4;MAP2K1;MAPK1;PDPK1;GSK3B;MAPK8;MTOR;RAF1;CHUK;MAP3K7;MAP3K14;CALM1;RAC1;CALM2;MAP2K5;MAPK7;MAP3K1;PRKCA
gsea,Allograft Rejection WP2328,0.2474666907831844,0.6369665305463226,0.8571428571428571,0.9827612857637075,1.0,4/89,19.01%,TUBA1B;GABPA;STAT1;VEGFA
gsea,Alzheimer's disease WP2059,0.18679731390323884,0.6280272067303808,0.9782608695652174,0.9842766259023633,1.0,5/83,7.11%,GAPDH;ATP5MD;PPP3R1;ADAM17;IDE
gsea,Eukaryotic Transcription Initiation WP405,0.15817996011938856,0.6223833637097276,0.9803921568627451,0.9831530296844929,1.0,18/43,40.07%,GTF2F2;POLR2B;GTF2H1;POLR2K;GTF2E2;TAF9;POLR2C;POLR3E;GTF2E1;POLR2E;TAF6;CCNH;GTF2B;GTF2A2;POLR1A;ERCC3;POLR1E;POLR1B
gsea,Hippo-Yap signaling pathway WP4537,-0.1967001867243433,-0.6133121213886465,0.9607843137254902,1.0,1.0,4/23,23.76%,MINK1;TEAD3;MAP4K4;TEAD2
gsea,Glucocorticoid Receptor Pathway WP2880,0.17647988159282968,0.6132844092385692,0.9183673469387755,0.9836072709860668,1.0,3/70,3.42%,B3GNT5;HSP90AA1;PRRG4
gsea,Proteoglycan biosynthesis WP4784,-0.25435255657850053,-0.6111354182151812,0.9090909090909091,1.0,1.0,7/18,24.84%,B3GAT3;B4GALT7;B3GALT6;SLC35B2;SLC35B3;EXT1;PAPSS2
gsea,Epithelial to mesenchymal transition in colorectal cancer WP4239,-0.14678791942521888,-0.606237361675153,0.9795918367346939,1.0,1.0,37/160,31.24%,PIK3CD;MAPK3;FOXQ1;MMP15;WNT5A;GDF15;JUP;COL4A5;CRB3;NR2C2;MAP2K2;CLDN4;MAPK13;MAPK14;CLDN7;CLDN23;MAPK11;AKT2;SMAD4;FZD7;WNT5B;CLDN12;GRB2;FZD2;WNT6;COL4A6;SNAI2;WNT7B;TP53;CTNNB1;CLDN3;WNT10A;CLDN9;LRP5;PDCD6;HRAS;TJP1
gsea,PI3K-AKT-mTOR signaling pathway and therapeutic opportunities WP3844,0.17303793500872613,0.6017121861173872,1.0,0.9850319506119354,1.0,8/30,29.18%,PIK3CB;NRAS;GSK3B;KRAS;MTOR;RPTOR;PIK3CA;RICTOR
gsea,Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway WP4577,0.15489495783401375,0.6006124872892402,1.0,0.9808809632458885,1.0,10/44,29.15%,ATG3;ATG4A;PIK3C3;SPTLC1;PIK3R4;PRKAA1;ACACA;MTOR;RPTOR;ATG7
gsea,Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) WP2817,-0.19272529867215105,-0.5979096135405451,0.96,1.0,1.0,4/32,17.05%,EGFR;ERBB2;CEBPB;MYC
gsea,1q21.1 copy number variation syndrome WP4905,-0.22605234863845403,-0.5947364710151055,0.9583333333333334,1.0,1.0,5/27,20.14%,PYGO2;PRKAG1;AFDN;BCL9;TJP2
gsea,DNA damage response (only ATM dependent) WP710,-0.15481742071477977,-0.5933519522800891,0.9787234042553191,1.0,1.0,28/110,29.42%,PIK3CD;BBC3;CAT;WNT5A;ERBB2;BAX;DVL2;CDKN2A;BAK1;DVL1;AKT2;BAD;MYC;SMAD4;BIK;DVL3;NFKB2;WNT5B;CCNG2;GRB2;WNT6;IRS1;WNT7B;BCL2L11;TP53;CTNNB1;WNT10A;RAC2
gsea,T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection WP3863,-0.1810574853829867,-0.5914863202276993,0.9787234042553191,1.0,1.0,9/62,24.25%,PTPN6;MAPK3;RRAS;MAP2K2;DLG1;NCK1;GRB2;NFKBIA;AHSA1
gsea,Development of ureteric collection system WP5053,-0.19090494168727243,-0.59054078663712,0.94,1.0,1.0,7/47,29.71%,RARG;GRIP1;ILK;GLI2;VANGL2;CTNNB1;FOXC1
gsea,Autophagy WP4923,0.1806230290344617,0.5903606481401705,1.0,0.9806314103022586,1.0,9/30,29.15%,ATG3;PIK3C3;PIK3R4;PRKAA1;AMBRA1;MTOR;ATG9A;RPTOR;ATG7
gsea,MicroRNAs in cardiomyocyte hypertrophy WP1544,-0.15027337478815717,-0.5898736589338237,0.9807692307692307,1.0,1.0,10/84,17.14%,PIK3CD;MAPK3;HDAC5;WNT5A;TAB1;MAP2K2;MAPK14;DVL1;AKT2;CTF1
gsea,Vitamin D in inflammatory diseases WP4482,-0.23856053273294933,-0.573058719569024,0.9230769230769231,1.0,1.0,6/22,24.33%,DUSP1;MAPK14;IL6;SMAD4;NFKBIA;PPP3CA
gsea,Lung fibrosis WP3624,-0.19325236148241967,-0.5648511909253342,0.9583333333333334,1.0,1.0,5/63,17.50%,SKIL;SMAD7;CEBPB;PDGFB;IL6
gsea,SARS-CoV-2 innate immunity evasion and cell-specific immune response WP5039,-0.1938827390200527,-0.548835817192664,1.0,0.9988060973164935,1.0,9/66,23.91%,TRADD;STAT2;IFITM1;IL6;TP53I3;RIPK1;TRAF2;MAVS;FADD
gsea,Intracellular trafficking proteins involved in CMT neuropathy WP4856,0.22681255023163105,0.5349591108593132,0.9333333333333333,0.9971062157631154,1.0,5/27,26.74%,FIG4;DNM2;RAB11A;RAB7A;KIF1B
gsea,Gastrin signaling pathway WP4659,-0.12791911573799292,-0.49769989750950494,1.0,1.0,1.0,15/114,17.23%,MAPK3;SLC9A3;EGFR;BCAR1;MAP3K11;YES1;CDKN2A;RHOB;ARRB2;MAPK14;PXN;ARRB1;BAD;MYC;PTGS2
gsea,Renin-angiotensin-aldosterone system (RAAS) WP4756,-0.1688836862828493,-0.4907149992625389,1.0,0.992133726647001,1.0,15/44,83.15%,ATF6B;CALM3;CALML5;ATF4;CREB3L1;ATF2;CREB3;CREB3L2;CAMK2G;ATF1;CALM2;CALM1;ITPR3;CREB1;GNAQ
gsea,IL17 signaling pathway WP2112,0.18003740567782944,0.48428675932845433,0.9767441860465116,1.0,1.0,9/32,39.56%,JAK1;MAPK1;GSK3B;TRAF3IP2;PIK3CA;SP1;MAP3K7;MAP3K14;TRAF3
gsea,Physiological and pathological hypertrophy of the heart WP1528,0.16471858628460423,0.48416181405882736,1.0,0.9974787100869228,1.0,7/25,37.38%,RHOA;MAPK1;MAPK8;IL6ST;CALM1;RAC1;CALM2
gsea,Target Of Rapamycin (TOR) Signaling WP1471,0.12127349557259036,0.44229385005197464,1.0,0.9970305787212534,1.0,11/36,39.23%,IDI1;FKBP1A;PRKAA1;MTOR;RPTOR;RICTOR;RPS6KB1;PRKAB1;RAC1;HMGCR;RRAGC
